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Neuronal mitochondrial dysfunction is a key pathophysiologic mechanism of diabetic 
peripheral neuropathy (DPN). KU-596 is a small molecule modulator of heat shock protein 
90 (Hsp90) that can reverse clinically relevant measures of DPN in diabetic animal models. 
Mechanistically, drug efficacy requires Hsp70 and correlates with improving 
mitochondrial bioenergetics (mtBE) in diabetic sensory neurons. The goal of this study was 
to determine if KU-596 improves mtBE by decreasing glucose-induced oxidative stress in 
an Hsp70-dependent manner. Sensory neurons were isolated from non-diabetic or diabetic 
mice wild type (WT) or Hsp70 knockout (Hsp70 KO) mice and treated ex vivo with KU-
596 in the presence of low or high glucose concentrations. In diabetic WT and Hsp70 KO 
neurons, hyperglycemia significantly increased superoxide levels, but KU-596 only 
decreased superoxide in WT neurons. Similarly, KU-596 significantly improved mtBE in 
hyperglycemically stressed diabetic WT neurons but did not improve mtBE in diabetic 
Hsp70 KO under the same conditions. Since manganese superoxide dismutase (MnSOD) 
is the main mechanism to detoxify mitochondrial superoxide radicals, we determined the 
cause and effect relationship between improved respiration and decreased oxidative stress 
by knocking down MnSOD. Downregulating MnSOD in diabetic WT neurons increased 
hyperglycemia-induced superoxide levels as measured by electron paramagnetic resonance 
spectroscopy and blocked the ability of KU-596 to enhance mtBE. In diabetic neurons, 
knockdown of MnSOD increased maximal respiratory capacity (MRC) and this was 
significantly decreased by mito-TEMPO-H after scavenging overproduced superoxide 
radicals. Following MnSOD knockdown, KU-596 decreased mitochondrial superoxide but 
was unable to improve MRC. Overall, this study shows that the Hsp90 inhibitor KU-596 
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improves mtBE and decreases mitochondrial oxidative stress of diabetic sensory neurons 
in an Hsp70-dependent manner. However, the drug-induced improvement of mtBE is not 
necessarily dependent on decreasing mitochondrial oxidative stress and other mechanisms 
can be modulated by novologue therapy to improve mtBE. This work furthers our 
mechanistic understanding by which novologue therapy can improve metabolic aspects of 
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Chapter 1. Background 
1.1 Diabetes Mellitus Overview 
Diabetes mellitus is a metabolic disease that develops when the body cannot secrete 
enough insulin or cannot respond to insulin effectively. Insulin is a hormone produced by 
pancreatic β cells, which is required to transport glucose from blood into the cells for 
energy. The lack or ineffectiveness of insulin in diabetic patients could lead to 
hyperglycemia, manifested as elevated levels of blood glucose. Over time, hyperglycemia 
causes damage to many tissues, leading to diabetic complications such as diabetic 
nephropathy, retinopathy and neuropathy.  
There are three major types of diabetes: Type 1 diabetes, Type 2 diabetes and 
gestational diabetes [1-3] that can be diagnosed based on fasting plasma glucose (FPG) 
levels or a 2-h plasma glucose (2-h PG) value after a 75-g oral glucose tolerance test 
(OGTT) [1]. Diabetes can also be diagnosed based on the attachment of glucose to 
hemoglobin using the A1c test, also called hemoglobin A1c or HbA1c test. Since the 
lifespan of hemoglobin is three months, HbA1c indicates the average blood glucose levels 
over this period. The HbA1c test result is reported as a percentage and the criteria point for 
a diagnosis of diabetes is set at 6.5% (Table 1.1.1). The A1c test has several advantages 
over plasma glucose tests, since it doesn’t require fasting, has greater analytical stability 
and less fluctuation. However, according to the American Diabetes Association, FPG is the 
preferred method for diagnosing diabetes since it is more convenient and less expensive. 
The standard diagnosis of diabetes is based on two separate blood glucose tests with FPG 
levels greater than 126 mg/dL. For individuals with a FPG of 110 - 124 mg/dL or an A1c 
of 6.0%–6.4%, a 2h-PG after 75-g OGTT tests should be given to verify diabetes [4]. 
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Table 1.1.1: Diagnosis criteria for diabetes mellitus 
 Normal Pre-Diabetes Diabetes 
A1c ( % ) Below 5.7 5.7 - 6.4 Above 6.5 
FPG ( mg/dL ) Below 110 111 - 125 Above 126 
2h-PG (mg/dL) during 
an 75-g OGTT 
Below 140 140 - 200 Above 200 
1.1.1 Type 1 Diabetes 
Type 1 diabetes usually occurs in children or young adults and is caused by 
autoimmune destruction of pancreatic β cells, after which the body cannot produce insulin. 
Type 1 diabetes is usually diagnosed by an elevated FPG level, together with sudden weight 
loss, abnormal thirst, dry mouth, frequent urination, lack of energy, and blurred vision. 
Type 1 diabetes patients need insulin every day to control their blood glucose levels for 
survival. Regular quick-acting human insulin and intermediate NPH (Neutral protamine 
Hagedorn) insulin and long acting insulin analogs are top options. With regular blood 
glucose monitoring and maintaining a healthy diet and lifestyle, Type 1 diabetes patients 
can lead a very normal and healthy life [5].  
The number of Type 1 diabetes patients is increasing. According to the National 
Diabetes Statistics Report of 2014, there are about 1.25 million Americans living with Type 
1 diabetes, including about 200,000 youth (less than 20 years old) and over a million adults 
(20 years old and older) [6]. More than 40,000 people are diagnosed each year in the U.S 
and about 14 billion dollars are spent on Type 1 diabetes in the US [7]. 
Immune factors and immune responses may induce and exacerbate the damage of 
pancreatic β cells to cause Type 1 diabetes. β-cell antigens can be recognized by antigen-
presenting cells (APCs) to stimulate insulin reactive CD4+ and CD8+ T cells differentiation 
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[8]. Activated T cells can directly kill β cells through a cytotoxic process. They can also 
induce the pro-inflammatory cytokines, granzyme B, perforin and even activate 
programmed cell death pathways. Other immune cells including B lymphocytes, natural 
killer (NK) cells and dendritic cells may also involve in the damage of pancreatic β cells, 
which ultimately lead to Type 1 diabetes [9].  
Type 1 diabetes can be induced by high dose streptozotocin (STZ) injections in 
rodents. STZ (Fig.1.1.1.1) is an antibiotic derived from the bacterium Streptomyces 
achromogens. It contains a deoxy glucose molecule to direct the chemical to the GLUT2 
transporter on the pancreatic β cells, while linking with a highly reactive methylnitrosourea 
moiety to mediate STZ’s cytotoxic effects by damaging DNA [10].  
It is generally assumed that the cytotoxic effect of STZ is dependent upon the DNA 
alkylating activity of its methylnitrosourea moiety [11, 12]. The transfer of the methyl 
group from STZ to the DNA molecule could cause a chain of damage, resulting in the 
fragmentation of the DNA. In compensation to repair DNA, poly (ADP-ribose) polymerase 
(PARP) is overstimulated resulting in a diminishment of cellular NAD+ and ATP reserves. 
The depletion of the cellular energy can ultimately lead to β cell necrosis. Furthermore, 
STZ can also methylate and glycosylate proteins to cause β cell defects [13].  
Though GLUT2 is mainly expressed on pancreatic β cells, lower levels also exist in 
the liver and kidneys. After IV administration, STZ has a half-life of 15 minutes. It is 
quickly metabolized in the liver and is rapidly eliminated by kidneys [14, 15]. Though high 
doses of STZ might impair liver and kidney functions, its long-term toxicity to the liver 
and kidneys is attributed to its induction of hyperglycemia [16]. This is further confirmed 
by Grossman’s report that insulin treatment to STZ diabetic mice can promote the 
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regeneration of diabetic pancreatic β cells. This suggests that after STZ elimination, further 
β cell dysfunction is due to hyperglycemia [17].  
 
Figure 1.1.1.1: Chemical structures of drugs inducing Type-1 diabetes. 
Alloxan (Fig.1.1.1.1) is another chemical to induce Type 1 diabetes. Alloxan is 
quickly taken up by β cells and reduced into dialuric acid, which is then re-oxidized to 
alloxan to produce a redox cycle. This redox cycle generates superoxide radicals that can 
be further converted into hydroxyl radicals and hydrogen peroxide, resulting in β cell DNA 
fragmentation. However, compared with STZ, alloxan induces diabetes in a narrow dose 
range, and slight overdosing can cause systemic toxicity, especially to the kidneys [18]. 
1.1.2 Type 2 Diabetes 
Type 2 diabetes is the most common type of diabetes that accounts for 90-95% of 
diagnosed cases. In 2012, over 29.1 million people in the United States had Type 2 diabetes, 
but 8.1 million may be undiagnosed and unaware of their condition. This disease usually 
affects adults, but the number of children and adolescents with diabetes is increasing 
rapidly. At the onset of Type 2 diabetes, the body is resistant to insulin, even with sufficient 
production by β cells. Over time, insulin levels may become inadequate and both the insulin 
resistance and deficiency can lead to hyperglycemia in Type 2 diabetes [3].  
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Many Type 2 diabetics are unaware of their condition for many years because 
hyperglycemia develops gradually and the classic symptoms are generally less marked than 
in Type 1 diabetes. However, during this process, the body is already being damaged by 
excess hyperglycemia and develops microvascular and macrovascular complications. 
Although the exact reasons for developing Type 2 diabetes are still not known, obesity, 
physical inactivity, poor nutrition, family history, previous diagnosis of gestational 
diabetes and advancing age could be associated with disease development [19]. 
Unlike Type 1 diabetes, most Type 2 diabetes patients do not require daily insulin 
therapy to survive, and can improve their glycemic regulation by adopting a healthy diet, 
increasing physical activity and controlling obesity. However, in the absence of adequate 
management of blood glucose by diet and exercise, a number of “blood glucose controlling” 
drugs can be prescribed. Metformin and sulfonylureas are on the World Health 
Organization list of essential medicines for diabetes [20, 21]. Other commonly used 
treatments for Type 2 diabetes include glucagon-like peptide 1 (GLP-1) analogues and 
dipeptidy peptidase 4 (DPP4) inhibitors. Both treatments can enhance the body’s natural 
response to ingested food and reduce blood glucose levels after eating [22]. 
Animal models of Type 2 diabetes tend to include insulin resistance models or β cell 
failure models. Since Type 2 diabetes development is closely associated with obesity in 
humans, most animal models of Type 2 diabetes are obese models. This can be achieved 
with genetic manipulation or high fat diet approaches. Although human obesity is rarely 
caused by a single gene mutation, monogenic mutations in leptin signaling to cause obesity 
are commonly used in Type 2 diabetes studies [23]. Leptin mediates satiety, and leptin 
deficiency leads to hyperphagia and subsequent obesity. Two mouse models of leptin 
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deficiency are Lepob/ob and Leprdb/db mice. In Lepob/ob mice, the leptin protein is mutated. 
Body weight starts to increase at 2 weeks, and the mice begin to develop hyperinsulinemia. 
By 4 weeks, hyperglycemia becomes apparent, and blood glucose continues to rise, 
peaking at 3-5 months. Other diabetic symptoms include hyperlipidemia and lower 
physical activity [24]. A second model is the Leprdb/db mouse that has a recessive mutation 
in the leptin receptor [25]. Hyperinsulinemia is apparent at around 2 weeks, obesity is 
evident starting from 3-4 weeks and hyperglycemia develops at 4-8 weeks [26].  
High fat diet can also lead to obesity, hyperinsulinemia and hyperglycemia due to 
impaired glucose tolerance. In a normal diet, about 26% of energy comes from protein, 63% 
from carbohydrates and 11% from fat. However, in a high fat diet, about 58% of energy 
comes from fat [27]. Within the first week of a high fat diet, mice are heavier than those 
on a normal diet, and several weeks of a high fat diet induces substantial weight gain. This 
gain of weight is associated with lack of β cell compensation and insulin resistance. Since 
obesity is usually manipulated by environmental factors rather than gene mutations in 
humans, the high fat diet model is a more relevant model than those based on genetically-
induced diabetes [23]. 
1.1.3 Gestational Diabetes 
Women with slightly elevated blood glucose levels are classified as having gestational 
diabetes and this tends to occur from the 24th week of pregnancy. Even though this 
normally disappears after birth, patients diagnosed with gestational diabetes are more likely 
to develop Type 2 diabetes later in pregnancy and later life. Infants born to mothers with 
gestational diabetes also have a higher risk of developing Type 2 diabetes in adolescents 
or early adulthood [28]. 4.6 to 9.2 Percent of pregnancies may be affected by gestational 
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diabetes with up to 10 percent diagnosed with Type 2 diabetes just after the pregnancy. 
The rest of these women have a 35 to 60 percent chance of developing Type 2 diabetes 
within 10 to 20 years. This risk decreases if the woman leads an active lifestyle and 
maintains an ideal weight [29]. 
1.1.4 Insulin Signaling 
Insulin resistance in patients with Type 2 diabetes is mainly due to the loss of cell 
signaling in response to insulin, which regulates glucose, lipid, and energy homeostasis in 
liver, adipose and skeletal muscle. Insulin and Insulin-like Growth Factor-1 (IGF-1) bind 
to tyrosine kinase-linked insulin and IGF-1 receptors (Fig.1.1.4.1). This initiates a cascade 
of phosphorylation reactions that activate phosphatidylinositol 3 kinase (PI3K) and protein 
kinase B (also called Akt) to regulate cellular metabolism. Perturbations in these signaling 
pathways can lead to insulin resistance.  
Upon binding with insulin, the receptors undergo a conformational change and auto-
phosphorylation which permits subsequent phosphorylation of downstream targets such as 
the insulin receptor substrate 1 (IRS-1) and the adapter protein, Shc. IRS-1 is responsible 
for many of the anabolic aspects of insulin signaling by activating the PI3K-Akt pathway. 
PI3K increases the membrane concentration of PI 3,4 bis-phosphate and PI 3,4,5 
trisphosphate which promotes the activity of phosphoinositol dependent kinase (PDK-1), 
the upstream activator of Akt. Akt mediates most of insulin’s metabolic effects, by 
increasing glucose transport, lipid synthesis, and glycogen synthesis while suppressing 
gluconeogenesis and glycogenolysis. On the other hand, Shc activates the RAS-MAPK 




Insulin signaling can be attenuated by several phosphatases that dephosphorylate 
receptors, IRS-1, MAPK and PI3,4 or 3,4,5 polyphosphates. Moreover, stress kinases, such 
as JNK (c-Jun N-terminal kinase), IKK (IκB kinase), PKC (Protein kinase C) and ERK 
(Extracellular signal-regulated protein kinases) can inhibit insulin/IGF-1 signaling 
pathway by inducing inhibitory serine/threonine phosphorylation of IR/IGFR and IRS 
proteins [30]. 
 
Figure 1.1.4.1: Positive pathway of insulin signaling 
1.1.5 Glucose Metabolism 
To generate energy, glucose needs to be metabolized inside the cells by glycolysis 
first. Once transported into the cell, glucose can be phosphorylated by hexokinases to 
glucose-6-phosphate. Glucose-6-P can undergo two routes, it can enter the pentose 
phosphate pathway to produce NADPH for use in anabolic reactions (Fig.1.1.5.1), or be 
converted into fructose-6-P by phosphoglucose isomerase to continue into glycolysis. The 
product of glycolysis is pyruvate, which enters the mitochondria to form acetyl CoA for 




Figure 1.1.5.1: Glycolysis pathway 
Glucose overload in diabetes can increase its flux through a minor metabolic pathway 
called the polyol pathway (Fig.1.1.5.2). In the polyol pathway, excess glucose is reduced 
into sorbitol by aldose reductase (AR) and oxidized to fructose by sorbitol dehydrogenase. 
This process consumes NADPH, a co-factor that is also essential for the conversion of 
oxidized glutathione (GSSH) to glutathione (GSH) via glutathione reductase. The 
utilization of NADPH in the polyol pathway can cause or exacerbate intracellular oxidative 
stress [32]. Additionally, an increase in fructose promotes excess formation of fructose 6-
phosphate, which is an entry substrate for flux through the hexosamine pathway. In the 
hexosamine pathway, fructose 6-phosphate is converted by the enzyme glutamine-
fructose-6-phosphate amidotransferase (GFAP) to UDP-N-Acetylglucosamine, which can 
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modify numerous proteins on Ser and Thr residues by forming O-linked N-
acetylglucosamine [33].  
Glucose accumulation can also over produce glyceraldehyde 3-phosphate, which can 
activate two major pathways involved in hyperglycemic complications. An increase in this 
triose phosphate can activate the glycation pathway by driving glyceraldehyde-3-
phosphate and dihydroxyacetone-3-phosphate into non-enzymatic synthesis of 
methylglyoxal. Advanced glycation end products (AGEs) are formed by the non-enzymatic 
reaction between the ketone or aldehyde groups of these trioses and the amino groups of 
proteins. Research has shown that accumulation of AGEs in diabetes is accelerated and 
activates the receptor of AGEs (RAGE). This can lead to the intracellular generation of 
Reactive oxygen species (ROS) by NADPH oxidase and causes downstream activation of 
redox-sensitive transcription factors such as the nuclear factor-κB (NF-κB) and vascular 
endothelial growth factor (VEGF) [34]. In the other pathway, glyceraldehyde 3-phosphate 




Figure 1.1.5.2: Hyperglycemic damage mechanism 
1.1.6 Diabetic Complications 
Prolonged hyperglycemia can lead to serious complications affecting the heart, 
kidneys, nerves and eyes. In diabetes, damage to small blood vessels can lead to 
microvascular complications, while damage to arteries can lead to macrovascular 
complications. Microvascular complications include retinopathy, nephropathy, and neural 
damage. The major macrovascular complications are cardiovascular disease resulting in 
myocardial infarction and strokes [36]. 
Retinopathy 
Diabetic retinopathy is a leading cause of blindness in adults and is associated with 
the development of progressively severe retinal lesions that damage vision. Diabetic 
retinopathy develops for many years, and almost all Type 1 diabetes patients [37], and most 
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Type 2 diabetes patients [38], can exhibit retinal lesion symptoms after more than 15 years 
of diabetes. However, retinal disorder is more severe in Type 1 than Type 2 diabetes.  
The pathologic signs of retinopathy include changes in vascular permeability, 
capillary micro-aneurysms, capillary degeneration, and excessive intra-retinal hemorrhage, 
accompanied with the formation of lipid exudates that causes regional failure of retinal 
microvascular circulation, blurred vision and blindness. Clinically, diabetic retinopathy can 
be classified into non-proliferative and proliferative stages. Non-proliferative diabetic 
retinopathy (NPDR) is the initial stage in which symptoms are mild and likely un-
noticeable. In NPDR, the blood vessels in the retina are weakened, and micro-aneurysms 
can be formed that may leak fluid into the retina. This leakage can lead to swelling of the 
macula, which is responsible for straight ahead vision. In the advanced proliferative stage, 
new blood vessels are formed and extend to the vitreous and cause hemorrhage and fluid 
accumulation within the retina. This leads to macula edema to cause visual impairment 
[39]. In more severe conditions, there can be bleeding due to fibrosis in retinal vascular 
membranes which can lead to retinal detachment [40]. 
There are three common treatments for diabetic retinopathy to improve vision loss, in 
addition to controlling blood pressure and glucose levels. These include retinal laser 
photocoagulation therapy, vitrectomy to remove the vitreous, or injection of VEGF 
antagonists into the eye since VEGF increases retinal angiogenesis [40, 41].  
Nephropathy 
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) 
due to microangiopathy, glomerular hypertrophy, thickening of glomerular basement 
membrane and enlarged glomerular mesangium [42, 43]. It is characterized by a chronic 
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inflammation, progressive loss of renal function, glomerular/tubular-interstitial scarring 
and albuminuria. Progression of the nephropathy can be classified into three stages. The 
first stage in early diabetes is glomerular hypertrophy characterized as glomerular 
hyperfiltration [44]. Glomerular hyperfiltration causes the damage to the preglomerular 
and glomerulus vessels, which are the filtering components of the kidney [45]. The kidneys 
then filter increased amounts of glucose, fatty acids, proteins, amino acids, growth factors, 
and cytokines which can trigger many pathologic pathways leading to energy imbalances, 
redox anomalies, inflammation and fibrosis. This leads to the second stage of inflammation 
within glomerular and tubulointerstitial regions. The third stage is a reduction of cell 
number by apoptosis and accumulation of extracellular matrix (ECM). The deposition of 
ECM in the tubular component of the kidney can cause tubulointerstitial fibrosis, which 
can be used to determine the progression of diabetic nephropathy [46]. 
Besides glycemic control, the most widely used therapies for the treatment of diabetic 
nephropathy are through controlling systemic or intra-glomerular hypertension. The first 
line treatment of diabetic nephropathy targets the renin-angiotensin system (RAS) 
including angiotensin II (ANG II) receptor antagonists and angiotensin converting enzyme 
(ACE) inhibitors [47]. It is noteworthy that early nephropathy is a major risk factor for 
initiating cardiovascular disease including heart attacks and stroke in diabetic patients [48]. 
This indicates that more attention should be paid to diabetic nephropathy development 
from the early stages.  
Cardiovascular Disease 
Diabetic Cardiovascular Disease (CVD) is ventricular dysfunction accounting for 
over half of diabetes related deaths [49]. In Type 2 diabetes, nephropathy is a major risk 
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factor for cardiomyopathy, along with poor glycemic control, continued high blood 
pressure and dyslipidemia [50]. Diabetic CVD symptoms include atherosclerosis, cardiac 
and diastolic dysfunction as well as myocardial infarction and stroke [51]. 
Cardiac endothelium is critical to controlling heart adhesiveness, permeability and 
integrity. Endothelial dysregulation drives atherosclerosis, leading to the entry of low-
density lipoproteins into the subendothelial space causing fatty streak formation. 
Eventually, this can lead to necrosis, and the formation of atherosclerotic plaques, which 
may block the blood vessel at the formation site. In the coronary or femoral circulation, 
embolization of blood vessels that obstruct the distant sites may destabilize and rupture, 
leading to unstable angina, myocardial infarction or stroke [52, 53]. In addition to 
myocardial damage, coronary artery disease and cardiomyopathy can also occur in diabetes 
[54]. Cardiomyopathy is characterized by diastolic dysfunction of the heart, an inability to 
relax and fill during diastole of the cardiac cycle. Myocardial sclerosis caused by 
hypertrophy and neuronal abnormalities leads to diastolic dysfunction due to cross-linking 
and ECM deposition. The main clinical consequence of diastolic dysfunction is exercise-
induced dyspnea, which hinders the ability of diabetic patients to exercise, an important 
aspect of obesity management in diabetes [55]. 
Diabetic individuals with CVD should be under strict glycemic control, taking anti-
hypertension drugs and consider lipid lowering therapy with statins or fibrates as well as 
antithrombotic agents, such as aspirin [56].  
1.2 Diabetic Peripheral Neuropathy (DPN) 
      Diabetic neuropathy is the most common diabetic complication and is characterized by 
both autonomic and somatic nerve disorders. According to National Institute of Diabetes, 
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Digestive and Kidney Diseases, about 60 to 70 percent of diabetic patients have some type 
of neuropathy. Nerve damage can occur in the feet, legs, hands, arms, digestive tract, heart 
and basically every organ system. Diabetic patients can experience neurological problems 
at any time, but risk increases with age, the duration of diabetes and problems controlling 
blood glucose levels. The highest incidence of neuropathy is among diabetic patients for at 
least 25 years [57].  
The autonomic nervous system consists of nerves innervating the heart, lungs, bone, 
fat, sweat glands, blood vessels, gastrointestinal and genitourinary systems. In diabetic 
autonomic neuropathy, the most commonly affected systems include the gastrointestinal 
tract, genitourinary and cardiovascular systems [58]. Gastrointestinal neuropathy can affect 
the esophagus, stomach and intestines causing pain, nausea, vomiting, diarrhea and 
constipation. Delayed gastric emptying can lead to slowed medication effect while sluggish 
peristalsis of the small intestine can cause bacterial overgrowth, worsened by the presence 
of hyperglycemia. Gastroparesis is alleviated by eating smaller, more frequent meals. 
However, it can be enhanced by drugs that slow gastric emptying, like incretin/amylin 
mimetics. Antibiotics can be used for bacterial suppression.  
Peripheral neuropathy is the most common type of diabetic neuropathy. It is distal, 
symmetric and bilateral damage to nerves of the feet, legs, hands, and arms, with a distal-
to-proximal gradient of severity, known as stocking-glove sensorimotor neuropathy [59]. 
DPN is a length-dependent disorder, and feet and legs are often affected before hands and 
arms. Symptoms of sensory neuropathy are numbness or insensitivity to pain or 
temperature change, tingling, burning, or prickling sensation, sharp pain or cramps, and 
extreme sensitivity to touch. Motor neuropathy is less common and may occur at a later 
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stage. Symptoms may include muscle weakness and loss of reflexes, especially at the ankle, 
affecting the way people walk [60]. Foot deformities, such as hammertoes may also occur. 
Infection and ulceration may happen on numb areas of the foot due to injury goes unnoticed. 
The cumulative lifetime incidence of diabetic foot ulcers may be as high as 25%. If the 
infection is not treated promptly, it may spread to the bone, and the foot may have to be 
amputated. Foot ulcers precede 84% of all diabetes-related lower leg amputations [61]. 
Many amputations are preventable if we can catch and treat minor problems in timely 
manner [62]. However, DPN is still the first leading cause of non-traumatic amputations, 
representing a serious medical, social and economic problem all over the world. 
1.2.1 Diagnosis of DPN 
Besides controlling blood glucose level, diabetic patients should have an annual foot 
exam to identify high-risk foot conditions. This exam should assess sensation, foot 
structure, vascular status, skin integrity and ankle reflexes [63]. Sensory perceptions should 
be assessed, particularly the sensation of vibration and touch due to damage to thinly 
myelinated Aδ and unmyelinated C fibers. Proprioception, the perception of position, may 
also be affected due to damage to large myelinated Aα and Aβ nerve fibers (Table.1.2.1) 
[64].  
There are several quantitative diagnostic tests can be used to determine the presence 
and type of diabetic peripheral neuropathy. Quantitative sensory testing (QST) can be used 
to determine a loss of neural sensation or sensitivity. Nerve conduction velocity studies can 
detect possible nerve damage by assessing the transmission of nerve impulses. Slowed 
transmission may indicate nerve damage. Electromyogram (EMG) can be used to assess 
how muscles respond to nerve impulses to determine if there is damage to muscle or neural 
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innervation [59, 65]. Loss of unmyelinated intra-epidermal nerve fibers (iENFs) in the feet 
is associated with loss of thermal sensitivity. Thus, assessing iENF density is becoming an 
important clinical measure of DPN [66]. 
Table 1.2.1: Sensory neuropathy test 
Sensory Modality Nerve Fiber Test Approach 
Pressure Aα, Aβ 1 and 10 g monofilament 
Light touch Aα, Aβ Wisp of cotton 
Vibration Aβ 128-Hz tuning fork 
Cold Aδ Cold tuning fork 
Pain (pin prick) C Neuro-tips 
1.2.2 Current Therapies for DPN 
Despite advanced understanding of DPN development, prevention is still a key goal 
of diabetes care due to the lack of effective treatments for peripheral nerve injury. 
Prevention of diabetic neuropathies includes tight glycemic control and lifestyle changes. 
Strict glycemic control in Type 1 diabetes patients significantly reduces the incidence of 
distal symmetric polyneuropathy. While in Type 2 diabetes patients with multiple 
complications, glycemic control alone is less effective at preventing distal symmetric 
polyneuropathy. For patients with pre-diabetes, Type-1 diabetes and Type-2 diabetes, 
lifestyle interventions such as exercise and dietary change are recommended for distal DPN 
prevention [67]. 
Although significant progress has been made in understanding the pathogenesis of 
diabetic neuropathy, pharmacotherapies are still limited. Antidepressant drugs, both of the 
tricyclic type and serotonin-norepinephrine reuptake inhibitors (SNRIs), are widely used 
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and are effective treatments for neuropathic pain, although only duloxetine (Cymbalta) is 
FDA approved for DPN [68]. Duloxetine is a selective norepinephrine and serotonin 
reuptake inhibitor. In multicenter clinical trials, doses of 60 and 120 mg/day showed strong 
efficacy in the treatment of DPN pain, despite its high drop-out rate [69]. Duloxetine can 
also improve diabetes-related quality of life. However, in longer-term studies, duloxetine 
treatment may cause a mild increase in A1c in diabetic patients compared with placebo 
treatment [70]. 
 Anticonvulsants drugs have also been effectively used in treating of neuropathic pain. 
The FDA has approved pregabalin (Lyrica) for treating painful DPN. It is widely used in 
treating abnormal pain, such as pins or needles sensations and burning. Pregabalin is a 
voltage-gated calcium channel α2-δ subunit ligand to reduce inappropriate calcium influx 
into the hypersensitive cells. It is an effective therapy for DPN neuropathic pain. By far, it 
is the most widely studied drug for DPN, with 30%–50% positive response rate for pain 
improvement [71].  
The opioids, in general, are effective in treating neuropathic pain, though they are not 
recommended as first-line treatments. Traditional opioids act on the mu-opioid receptor 
primarily. Tramadol has a dual effect of blocking norepinephrine uptake and acting on the 
mu-opioid receptor. Although there is no FDA approval for the treatment of DPN, these 
drugs are effective [72]. The problem with opioids are side effects, and very few people 
can tolerate particularly high doses. Nausea, constipation and even habituation are 
commonly observed [73]. 
In addition to these systemic therapies, topical medications like lidocaine patches or 
capsaicin cream may also be used to treat neuropathic pain. The lidocaine patch is a 5% 
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impregnation into a patch that you place on the skin. It is thought to act by blocking sodium 
channels, and because the sodium channels set up the afferent signal traffic, ectopic nerve 
impulses are suppressed. Capsaicin, which is the active component in hot pepper oil, acts 
differently. It depletes substance P in the skin, which mediates pain. It also blocks the 
vanilloid receptor to reduce pain [74, 75]. 
1.2.3 Peripheral Nervous System (PNS) Composition 
The two major components of the nervous system are the central nervous system 
(CNS) and peripheral nervous system (PNS). The PNS consists of 12 cranial nerves and 
31 pairs of spinal nerves. Efferent axons from motor neurons transmit information from 
the CNS to muscles and glands, whereas afferent axons from sensory neurons carry 
information from peripheral sensory receptors to the CNS [76].  
The sciatic nerve is the longest nerve in PNS, extending from the rear of the pelvis to 
the back of the thigh. It is the main nerve of the leg controlling the muscles of the hip and 
lower extremities. Other major peripheral nerves include the tibial nerve and sural nerve. 
The tibial nerve is a branch of the sciatic nerve that passes sensation to the soles. It controls 
the calf muscles, allowing the toes and feet to flex. The sural nerve consisting of medial 
and lateral branches is the sensory nerve in the leg. It passes sensory signals from feet and 
legs to the spinal cord and brain [77].  
DPN is a length-dependent, sensory more than motor, axonal neuropathy. At least two 
explanations have been made to illustrate why longer nerves and their axons usually get 
wounded before shorter ones. Sensory axons can be up to 3 feet or longer. The long length 
of these axons make them more vulnerable to blood-born or systemic damage. Another 
reason may be due to the supply of molecules and/or nutrients is harder to be transported 
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to more distal nerve terminals. These nerve ends therefore shrink and then disappear [78]. 
Diabetic sensory neuropathy usually precedes the involvement of motor neurons, which 
affects either or both the small and large nerve fibers in limbs [79].  
As summarized in Table.1.2.2 [80], peripheral sensory nerve fibers are classified into 
large myelinated Aβ-fibers, small thinly myelinated Aδ-fibers and unmyelinated C-fibers. 
Aβ-nerve fibers transmit sensation of proprioception, vibration, and pressure, while C-
fibers can sense warm and cold temperature change and harmful input with high threshold 
[80]. There are more unmyelinated than myelinated axons in the PNS, and these C fibers 
are majorly involved in PNS impairment. C fibers carry information for the autonomic 
nervous system as well as afferent impulses in response to temperature and noxious stimuli 
that could cause tissue damage. The earliest pathological nerve changes in DPN occur at 
unmyelinated C fibers, with initial degeneration and regeneration of C fibers resulting in 
pain, allodynia, and hyperesthesias [81]. As DPN progresses, degeneration exceeds 
regeneration, leading to C fibers loss. This C-fiber loss can also be observed in pre-diabetic 
patients. Comparing with myelinated fibers, unmyelinated C fibers are more vulnerable to 
metabolic damage mainly due to the lack of protection and nutritional supplementation by 
Schwann cells (SCs). After C-fiber atrophy, myelinated axons may undergo segmental 
demyelination and remyelination [81, 82]. As demyelination overrides remyelination, there 
is axonal degeneration of myelinated fibers. This temporal course of nerve pathology in 
DPN argues for a loss of protective and nutrient flow from the SCs to the myelinated axons, 
leading to eventual axonal loss. Furthermore, DPN develops in a distal-to-proximal manner 
along the nerve [83]. 
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Table 1.2.2:  Motor and Sensory Nerve Fibers in PNS 





















Hyperalgesia Hypoalgesia Hypoalgesia 
Hypoesthesia Hypoesthesia Hypoesthesia 
 
1.2.4 Pathogenesis of Diabetic Neuropathy Development 
Schwann Cell Pathology 
SCs are glial cells that myelinate axons to ensure rapid and efficient nerve conduction. 
The myelin sheath electrically insulates axonal membranes and allows fast propagation of 
nerve impulses by saltatory conduction. SCs maintain neuronal structure and function, 
nourish axons, and promote survival and growth upon injury and this is disturbed in 
diabetes. SCs express a wide range of receptors, and they upregulate the synthesis and 
secretion of neuroprotecitve factors that promote neuron regrowth and remyelination [84, 
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85]. Schwannopathy accompanied by axonal degeneration is a key pathology in DPN 
development [86].  
Proliferating SCs are more glycolytic, delivering pyruvate and lactate to axons, but 
SC mitochondrial dysfunction can cause SC degeneration leading to demyelination [87-
89]. During diabetes, SCs can lose their ability to provide energy to myelinated and 
unmyelinated axons and transfer toxic lipid species to the axons they contact. Disruption 
of their metabolism results in the accumulation of neurotoxic intermediates and 
compromises production of neuronal support factors, contributing to axonal degeneration, 
endothelial dysfuction and diabetic neuropathy [87].  
Polyol Pathway 
Excessive glucose in diabetes can activate the polyol pathway to produce sorbitol by 
the action of aldose reductase. The accumulation of sorbitol results in an osmotic imbalance 
in the cell to cause cellular and organ injury. Increased sorbitol decreases myo-inositol in 
peripheral nerves, which is an essential component of sodium/potassium (Na/K) ATPase. 
Aldose reductase activity also consumes NADPH, which can decrease GSH levels [90]. 
Since GSH is an important ROS scavenger, reduced GSH can cause or exacerbate 
intracellular oxidative stress. Excessive ROS can impair SC as well as endothelial functions 
that can reduce and contribute to poor blood flow in DPN [91]. 
Several drugs have been designed to inhibit aldose reductase and target the polyol 
pathway to treat DPN. Examples of such compounds include spirohydantoins (sorbinil) 
and carboxylic acid derivatives (tolrestat, fidarestat, and epalrestat). Clinical trials over the 
past decade have assessed the efficacy of these agents in treating diabetic retinopathy, 
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neuropathy, and nephropathy. Although some positive results have been reported, the 
benefits have generally been minimal and of no substantive clinical importance [92].  
Sorbinil is efficacious in preventing neurological dysfunction in the STZ mouse model. 
It reverses the accumulation of sorbitol, promotes the recovery of myo-inositol and slightly 
improves nerve conduction velocity (NCV). Although nerve conduction velocities were 
increased by sorbinil in the peroneal nerve — but not in the median motor or sensory nerves 
— no amelioration of early clinical signs or symptoms of diabetic neuropathy was observed 
[93]. Moreover, it has been withdrawn from further use because of its severe and frequent 
toxicity [94].  
Tolrestat was also withdrawn from the worldwide market in 1998 after the appearance 
of severe liver toxicity (including one case of hepatic necrosis reported from Italy) and the 
failure of clinical trials to demonstrate clear benefit [95, 96]. Fidarestat is a specific and 
potent aldose reductase inhibitor [97]. Significant improvement in electrophysiological 
measures of nerve conduction in motor and sensory nerves was observed with fidarestat 
treatment along with an improvement in numbness, spontaneous pain, sensation of rigidity, 
paresthesia in the soles upon walking, foot heaviness, and hyperesthesia. However, no 
other clinical trials of fidarestat have been reported since 2005. Epalrestat was well 
tolerated and significantly prevented deterioration of median nerve MNCV while 
preserving vibration perception threshold seen in the control group [98]. Overall, the lack 
of strong efficacy of aldose reductase inhibitors in clinical trials has limited the use of these 




Excessive flux of glucose through glycolysis can cause the accumulation of fructose-
6-phosphate. This glycolytic intermediate can be metabolized into glucosamine-6-
phosphate (GlcN-6-P) by fructose-6-phosphate amidotranferase (GFAT). GlcN-6-P can be 
further converted into uridine 5-diphosphate-N-acetylglucosamine (UDP-GlcNAc) to enter 
the hexosamine biosynthesis pathway. UDP-GlcNac is one of the sugar moieties that can 
cause protein and lipid glycosylation. UDP-GlcNac binds to O-linkage of serine/threonine 
residues of various proteins, including transcription factors like Sp1, c-myc and CREB [99-
102]. Overstimulation of the hexosamine pathway is related with insulin resistance, lipid 
dyshomeostasis, inflammation, and vascular complications in peripheral nerves [103]. No 
therapeutics that directly target this pathway to treat DPN have been developed. 
Protein Kinase C (PKC) Pathway 
Increased glycolysis can also cause the accumulation of glyceraldehyde-3-phosphate 
which can be metabolized to diacylglycerol (DAG). An increase in DAG can activate 
neuronal PKC and phosphorylate transcription factors to regulate protein expressions [104]. 
PKC is a family of serine/threonine protein kinases, including the isoforms of PKC-α, 
PKC-β1, PKC-β2, PKC-γ and PKC-ε. Activated PKC can cause changes in blood flow, 
endothelial dysfunction, increased vascular permeability, angiogenesis, cell growth and 
apoptosis, vessel dilation, basement membrane thickening and extracellular matrix 
expansion, abnormal angiogenesis, altered MAPK activity and disrupted Na/K ATPase 
activity [105]. Reduced Na/K ATPase activity leads to reduced nerve conduction and 
neuroregeneration. All PKC isoforms are expressed in nerve [106] and the PKC-β inhibitor 
ruboxiastaurin (LY333531, RBX) is a type of bisindoylmaleimide that was found to reverse 
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diabetic retinopathy and nephropathy. Ruboxiastaurin has a slight beneficial effect in the 
treatment of neuropathy sensory symptoms [107] but it is not approved to treat DPN. 
Advanced Glycation Pathway 
Another significant alteration induced by hyperglycemia is the non-enzymatic 
glycation of proteins via AGE formation [108]. Glucose and some glycolytic intermediates 
can be metabolized into α, β-dicarbonyls through Schiff base formation, Amadori and 
Maillard reactions. Dicarbonyls can react with amino groups of proteins, nucleotides and 
lipids to form AGEs. Proteins with more abundant lysine, arginine and cysteine residues 
are more easily glycated, which can cause changes in protein structure and function. 
Nucleotides with deoxyguanosines and lipids with basic phospholipids may also undergo 
glycation which can cause DNA mutation and affect membrane integrity [109, 110]. AGEs 
can also interact with their membrane receptors - RAGE to activate pro-inflammatory 
NFκB pathway and its downstream factors like MAPK, p21 and JNK [111, 112], causing 
multiple pathological changes. 
In diabetic patients, there is an increase in both intra- and extracellular AGEs [113]. 
A few drugs have been found to alleviate symptoms of diabetes by reducing AGEs. For 
example, metformin which is a common drug for Type 2 diabetes, can reduce serum 
reactive dicarbonyls and AGEs levels in Type 2 diabetic patients [114]. Pyridoxamine also 
relieves diabetic nephropathy by reducing carboxymethyllysine (CML) formation [115]. 
Pioglitazone and aminoguanidine also have anti-AGE effects [116]. AGEs have been found 
to play a critical role in the pathology of DPN. In diabetic dorsal root ganglia, AGEs can 
decrease mitochondrial respiratory chain activity and mitochondrial membrane potential 
[117-119]. AGEs can not only modify mitochondrial components and affect cellular 
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bioenergetics, but also modify matrix protein like laminin and fibronectin to blunt axonal 
regeneration and collateral stretching [117]. 
1.3 Oxidative Stress  
Poloyl pathway flux, overactivity of the hexosamine pathway, activation of PKC 
isoforms and increased AGEs formation can increase oxidative stress in both the cytoplasm 
and mitochondria. Another major endogenous source of ROS within most mammalian cells 
is through mitochondrial respiratory chain activity, which transports electrons to react with 
oxygen and generate ATP. However, about 0.1-2% of electrons may leak from complex I 
and complex III and incompletely reduce about 1-5% of total oxygen, producing 
superoxide radical ·O2
- to cause oxidative damage [120, 121]. 
1.3.1 Overview of Cellular Oxidative Stress 
In cellular oxidative metabolism, ROS mainly refer to superoxide anion (·O2
-), 
hydroxyl radical (·OH), hydrogen peroxide (H2O2), singlet oxygen (O), and organic 
hydroperoxides (ROOH) [122]. Cellular antioxidant defense systems act to detoxify these 
species at low concentrations. Low levels of ROS can be beneficial because they are 
required for certain biological processes including enzyme activation, gene expression and 
signal transduction. But over-accumulation of ROS can overwhelm antioxidant defenses 
leading to excessive oxidative stress and subsequent damage to many intracellular 
molecules including DNA, lipids, and proteins [123, 124]. More specifically, ROS can 
cause DNA mutations by oxidizing purines and pyrimidines [125]. As cell membranes are 
rich in polyunsaturated lipids, their integrity can be disrupted when oxidized by ROS [126]. 
Proteins, especially those with a high abundance of arginine, proline, threonine and 
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cysteine residues, can also be oxidized by ROS to alter their structure and function [127, 
128]. 
Oxidative stress is the result of the imbalance between ROS production and 
detoxification. As electrons traverse the mitochondrial respiratory chain, electrons may 
leak from complexes I and III, to reduce oxygen into superoxide radical ·O2
- [120, 121]. 
As superoxide contains one electron on the outermost orbital, it cannot penetrate lipid 
membranes, thus the majority of ·O2
- remains in the mitochondria [129]. To protect cells 
against oxidative damage, defensive mechanisms have evolved to eliminate surplus ROS. 
Mitochondrial manganese-dependent superoxide dismutase (MnSOD), cytoplasmic 
Cu/Zn-SOD and extracellular ecSOD can dismutate O2
- radicals to H2O2 or molecular 
oxygen. Even though H2O2 can be processed into oxygen and water by catalase and 
glutathione peroxidase, excessive H2O2 can still diffuse through mitochondria and further 
initiate many types of cellular injury [130]. For example, increased H2O2 is found in 
melanoma, ovarian and colon carcinomas [131] and it is recognized as a key messenger 
molecule to regulate cancer signal pathways, like NFκB activation [132]. When reduced 
transition metals (ions of Fe2+, Cu2+ or Co2+) react with H2O2 through the Fenton reaction, 
the •OH is the major product [133]. •OH is able to damage the deoxyribose backbone of 
DNA causing strand breaks and modify all four DNA bases, resulting in damage to mtDNA 
and mitochondria dysfunction [134].  
Other sources of ROS production include peroxisomes and oxidation enzymes. 
Peroxisomes contain oxidative enzymes such as D-amino acid oxidase, and uric acid 
oxidase. They can remove hydrogen atoms from specific organic substrates to react with 
oxygen and produce hydrogen peroxide. In addition, ROS can also be produced by a family 
of membrane-bound enzymes NADPH oxidases, which can affect cell proliferation and 
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apoptosis [135]. NADPH oxidases can be found in the plasma membrane as well as in 
phagosomal membranes, which are used by neutrophils to engulf microorganisms. During 
inflammation, leukocytes and mast cells are recruited to the damage site, which leads to a 
respiratory burst by increasing the uptake of oxygen and an accumulation of ROS [136]. 
Other enzymatic sources of ROS include cyclooxygenase, xanthine and nitric oxide 
synthase. 
1.3.2 Mitochondrial Oxidative Stress 
 Mitochondria are crucial cell organelles to regulate cellular functions, metabolism, 
and cell death in neurodegenerative diseases. They are not only the major source of ROS 
generation but also sensitive targets of oxygen radicals [137, 138]. In mitochondrial inner 
membrane, Complex I (NADH coenzyme Q reductase) receives electrons from NADH, 
and delivers them to coenzyme Q, which also receives electrons from complex II (succinate 
dehydrogenase). Coenzyme Q transports electrons to cytochrome c. Cytochrome c then 
transfers electrons to complex IV, which uses hydrogen ions and electrons to reduce 
oxygen into water. Meanwhile, complex I, complex II and complex IV pump hydrogen 
ions into the intermembrane space, creating an electrochemical gradient across the inner 
membrane that is essential for generating ATP. Because of electron leakage, complexes I 
and III of the electron-transport chain are the major sites for ROS production. Blockade of 
complex I by rotenone increases the reduction of the NADH dehydrogenase site of complex 
I, increasing electron leak to ROS [139]. Antimycin A obstructs complex III at the Qi center 
and increases superoxide generation from the Qo center [140-142]. The superoxide 
produced by complexes I and III can in turn inactivate NADH dehydrogenase, succinate 
dehydrogenase and ATP synthase activities. Other ROS, like hydrogen peroxide, can also 
partially inhibit NADH dehydrogenase and cytochrome oxidase [143, 144]. Thus, 
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oxidative stress can inhibit electron transport and decrease oxygen consumption and ATP 
generation.  
Mitochondrial membrane potential (Δψ) is also a crucial parameter for ATP formation 
and mitochondria function. ROS can oxidize unsaturated phospholipids on the inner 
mitochondrial membrane leading to increased permeability of the membrane that impairs 
mitochondria function [145]. In addition, Jendrach’s group showed that H2O2 can enhance 
fission factors including Drp1, Fis1 and MTP18 while increasing Mfn1 slightly [146, 147]. 
Thus, ROS generation can cause mitochondrial fragmentation. As most of the 
mitochondrial proteins are not synthesized in mitochondria, the intake of preproteins is also 
a major parameter to assess mitochondrial bioenergetics. Gary’s group showed that 
paraquat, a superoxide-generating molecule, could inhibit the import process of 
mitochondrial preproteins which are synthesized in the cytosol [148]. 
The main non-mitochondrial pathway for superoxide production is through NADPH 
oxidase. This enzyme is a membrane-bound electron transport complex. It receives 
electrons from NADPH and transport electrons across membrane into intracellular and 
extracellular compartments, such as mitochondria, nucleus, ER, endosomes, phagosomes 
and the extracellular space. It is the only major enzyme that produces superoxide and/or 
hydrogen peroxide and is used primarily to prevent pathogen spreading and kill bacteria. 
NAD(P)H oxidase activity generates superoxide radicals that promotes mitochondrial 
dysfunction and apoptosis in neurodegeneration. Overtime, accumulating ROS impairs 
neurological function and results in diabetic neuropathy development. 
SOD is the major ROS defense system. MnSOD localizes in mitochondria, while 
CuZn-SOD is expressed in cytosol to detoxify superoxide radicals. H2O2 is degraded by 
GSH peroxidase or catalase. GSH peroxidase reduces H2O2, in which two gluthathione 
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(GSH) molecules are oxidized to glutathione disulfide (GSSG). GSH-reductase is used to 
regenerate GSH, consuming NADPH to NADP+. Catalase is localized in peroxisomes to 
detoxify H2O2 into water and oxygen in the cytosol. 
Fluorescent measurements can be used to determine ROS production. Mitochondria-
targeted dihydroethidine (DHE), known as MitoSOX can be used to determine 
mitochondrial superoxide levels by staining with live cells. Triphenylphosphonium cation 
on MitoSOX allows its accumulation in the negatively charged mitochondrial matrix 
depending on mitochondrial membrane potential [149]. Another specific method to 
measure ROS is through Electron Paramagnetic Resonance (EPR) spectroscopy. The ROS 
level can be determined by wave signals generated by the interaction of free radicals with 
spin traps, like mitoTEMPO [150]. 
1.3.3 Antioxidant Therapy 
In addition to the antioxidant enzymes including SOD, glutathione peroxidase and 
catalase, there are several small antioxidant molecules that are of importance in the 
antioxidant defense system, especially where antioxidant enzymes are absent or present 
only in small amount. The lipid-soluble antioxidants are localized at cellular membranes 
and lipoproteins, whereas the water-soluble antioxidants are present in aqueous fluids, such 
as blood and the fluids within cells and surrounding them.  
α-Lipoic acid (ALA) 
α-Lipoic acid (ALA), also known as thioctic acid, is a cofactor for pyruvate 
dehydrogenase to decarboxylate pyruvate into acetyl-CoA [151]. It is taken up from the 
diet and is permeable to the blood-brain barrier. ALA contains two thiol groups that can be 
oxidized or reduced into dihydrolipoic acid. Both reduced and oxidized forms are strong 
antioxidants to scavenge ROS, regenerate other antioxidants such as vitamin C, vitamin E, 
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chelating metal ions and regulating gene transcription [152]. ALA treatment improves 
nerve conduction deficits in STZ diabetic rat but has shown limited efficacy in humans 
[153]. 
Vitamins E and C 
Vitamins E and C scavenge free radicals. Vitamin E is a lipophilic antioxidant which 
includes tocopherols and tocotrienols. Tocopherol, the biologically and chemically most 
active form of vitamin E, is by far the most abundant lipid-soluble antioxidant in humans 
[154]. Vitamin E reacts with hydroxyl radicals to form a stabilized phenolic radical which 
can be reduced back to the phenol by ascorbate and NAD(P)H dependent reductase 
enzymes [155]. Vitamin E has been reported to alleviate symptoms of diabetes and diabetic 
complications in animal models through reducing oxidative stress [156-158]. Treatment of 
Vitamin E reduced the incidence of sensory neuropathy [159-161]. Vitamin C, also known 
as ascorbic acid, is the prominent water-soluble antioxidant effectively scavenging ROS. 
In ob/ob Type 2 diabetic mice, vitamin C supplementation can cause significant reductions 
in food intake, HbA1c levels and plasma glucose levels, when compared with untreated 
control ob/ob mice [162]. 
Ubiquinone (Coenzyme Q10) 
Coenzyme Q10 also known as ubiquinone is an important vitamin-like micronutrient 
acting on the mitochondrial electron transport chain of ATP synthesis. CoQ transfers 
electrons from NADH at complexes I, succinate at complex II, and glycerol-3-phosphate 
of complex III to generate ATP. Coenzyme Q10 deficiency is common in Type 2 diabetic 
patients. In addition, CoQ10 is also a lipid-soluble antioxidant, that can be reduced to 
ubiquinol and redistributed into lipoproteins, to scavenge free radicals and protect cells 
from oxidation [163]. Plasma levels of CoQ10 are significantly lower in T2DM patients 
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than in healthy individuals [164]. Exogenous treatment of CoQ10 can potentially reduce 
oxidative stress-induced mitochondrial dysfunction, and improve glycemic control in Type 
2 diabetic patients [165]. However, its efficacy in human DPN is limited. 
Tempol and mitoTEMPO 
Tempol is a small molecule, water-soluble and membrane permeable SOD mimetic 
that is widely used in electron spin resonance spectroscopy [166]. Tempol reacts with both 
intracellular and extracellular superoxide radicals, to protect cells against oxidative stress 
[167]. Tempol can be used as an antioxidant in animal models to prevent many diseases 
that are caused by ROS such as ischemic-reperfusion injury, inflammation and diabetes 
[168, 169]. In vivo treatment with Tempol reduces NADPH oxidase activity, attenuates 
renal ER stress, inflammation and subsequent kidney damage in the STZ induced Type-1 
diabetes rat model [170].  
Mito-TEMPO is also a SOD mimetic, which passes through lipid bilayers easily and 
accumulates selectively in mitochondria. mito-TEMPO is a mitochondria-targeted 
antioxidant with superoxide and alkyl radical scavenging properties [171]. In vivo 
treatment with mito-TEMPO decreases mitochondrial oxidative stress in cardiomyocytes 
and improves cardiomyopathy in Type-1 and Type-2 mouse models of diabetes [172]. 
1.3.4 Oxidative Stress in DPN Development 
Increased ROS generation and impaired defense systems result in excessive 
oxidative stress and are major contributors to the pathogenesis of DPN [173]. In Type 1 
and Type 2 diabetic patients, plasma lipid peroxidation products increase while GSH and 
GSH-metabolizing enzymes decrease with disease development. This is closely related 
with the onset of diabetic complications [174-177]. Persistent hyperglycemia leads to ROS-
induced injury in diabetic neuropathy, and the relationship between ROS and neuropathy 
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in DM has been assessed using in vitro and in vivo models. In DPN, increased oxidative 
stress can disturb neural functions, decrease neurotrophic support and mediate apoptosis of 
neurons and Schwann cells [178, 179].  
Glucose-induced oxidative stress and changes in antioxidant capacity have been 
studied in different in vitro models. 10 - 20 mM additional glucose in rat DRG sensory 
neurons promotes superoxide and hydrogen peroxide overproduction. This can lead to lipid 
oxidation and even neuronal death, which can be prevented in part through decreasing ROS 
production with IGF-I [180]. In vitro incubation of sciatic nerve in 20 mM glucose medium 
increased lipid peroxidation up to four-fold that was partially prevented by the addition of 
α-lipoic acid to the medium [181]. Lipid peroxidation of nerve membrane could cause 
peripheral nerve ischemia and hypoxia, features of DPN [182].  
Glutathione and SOD levels were decreased in SCs cultured under high glucose and 
the NADH/NAD+ ratio progressively increased with higher glucose concentrations [183, 
184]. In adult sensory neurons isolated from STZ diabetic rats, hyperglycemia induced a 
robust increase in superoxide levels and this was associated with neurite degeneration and 
apoptosis [185, 186].  
Excessive oxidative stress can activate several inflammatory pathways and peripheral 
nerves undergo a pro-inflammatory process in DPN [187]. Inflammatory factors such as 
C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-
1) and tumor necrosis factor-α (TNF-α) are present in both Type 1 and Type 2 diabetic 
patients and correlate with the development of DPN [188]. TNF-α, transforming growth 
factor-β (TGF-β), and NF-κB can be activated by several glucose-induced pathways [189]. 
Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are important 
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enzymes that could be up-regulated by NF-κB in diabetic peripheral nerves and 
consecutively generate prostaglandin E2 and ROS that trigger further activation of NF-κB. 
Infiltration of macrophages and granulocytes takes place in diabetic peripheral nerves after 
ischemia reperfusion [190]. NF-κB activation induces cytokines in neurons, SCs and 
endothelial cells leading to absorption of macrophages in the diabetic nerves. Macrophages 
promote DPN via releasing cytokines, ROS, and proteases, which could lead to cellular 
oxidative damage, myelin breakdown and impair nerves regeneration in DPN [187, 191, 
192]. 
Excessive oxidative stress can disrupt mitochondrial membrane potentials which 
leads to swelling of neural mitochondria and mitochondrial dysfunction [179]. High 
glucose in DRG culture medium can lead to ROS accumulation in sensory neurons, which 
can initiate mitochondria swelling, hyperpolarization, and then depolarization, to release 
cytochrome c into the cytosol. Cytochrome c efflux activates apoptosis-activating factor 1 
(Apaf-1), caspase-3 and -9, with the formation of a cytochrome c/caspase-9/Apaf-1 
complex (the apoptosome), resulting in DRG apoptosis [193]. In primary sensory neurons 
from Type-1 diabetic rats, there was a down-regulation of Bcl-2 to initiate apoptosis [180, 
194]. High glucose induced neuronal apoptosis both in vivo and in vitro [195, 196], but 
apoptosis is not thought to be an important pathogenetic feature for the development of 
DPN [179].  
1.4 Mitochondria Dysfunction in Diabetes 
Mitochondria are important organelles that produce energy through oxidizing products 
of glucose metabolism. Mitochondrial bioenergetics are important for cellular energy 
generation via ATP synthesis and has become a keystone of research since the late 1940s 
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[197]. In diabetes, both metabolic and vascular insults can increase cellular oxidative stress 
to cause impaired glucose tolerance, insulin resistance and β-cell dysfunction [198]. In 
mitochondria, oxidative stress can modify mitochondrial DNA, proteins, and membrane 
lipids, to impair mitochondrial functions in sensory neurons. It should be noted that axons 
are disposed to hyperglycemic damage owing to their large content of mitochondria and 
diabetic mitochondria often show a decrease in respiratory function and mitochondrial 
membrane potential (MMP) [199].  
1.4.1 Mitochondrial Morphology 
Mitochondria are dynamic organelles that change in number and shape during 
development. Mitochondria constantly fuse and divide and an imbalance of the two 
processes can cause an overall change in mitochondrial morphology [200]. Recent studies 
have shown that abnormal changes in mitochondrial morphology can reduce respiratory 
capacity and increase ROS formation. Normal mitochondria appear as thin filaments 
microscopically [201], while under diabetic conditions, the mitochondria swell, and change 
from a filamentous shape to a spherical and dilated shape. In the STZ-induced Type 1 
diabetic model, there was a loss of cristae within mitochondria in skeletal muscle. This was 
accompanied with an increase of electron-dense granules and lipid droplets formation 
around the mitochondria [202]. In alloxan-induced diabetic rats, there was a decrease in 
mitochondrial number and mitochondrial membrane damage in hepatocytes and 
cardiomyocytes. The impaired mitochondria were round, swelled, had shorter cristae and 
less dense granules as well as exhibited a foamy and vacuolated matrix. These shape 
changes may indicate that the mitochondria are losing regular respiratory functions under 
diabetic conditions [203]. 
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1.4.2 Mitochondrial Membrane Potential 
Mitochondrial membrane potential is generated by protons pumped into the 
intermembrane space at complexes I, III, and IV and the resultant proton flux back into 
matrix. The flow of protons into the matrix that is not coupled to ATP generation is referred 
to as proton leak or uncoupled respiration. However, in most cells including neurons, most 
of the proton flux into the matrix is coupled to ATP generation.  
The mitochondria membrane potential (Δψ) is an important parameter to assess 
mitochondria bioenergetics, as it reflects the pumping of hydrogen ions across the inner 
mitochondrial membrane during the process of electron transport and oxidative 
phosphorylation, which is the driving force behind ATP production [204]. Mitchell’s 
chemiosmotic theory explains that mitochondrial respiration can create a transmembrane 
electric potential by generating a electrochemical gradient of protons across the inner 
membrane, which can in turn regulates the overall electron transport rate in the respiratory 
chain to generate ATP [205, 206]. 
In adult sensory neurons isolated from STZ induced diabetic rats, there was 
depolarization of the mitochondrial Δψ at 3- to 6-week of diabetes. Sensory neurons from 
STZ diabetic animals had a 50% decrease in the level of the mitochondrial Δψ compared 
with age-matched control animals and this could be prevented by insulin treatment [194], 
indicating that depolarization of the mitochondrial membrane in diabetes was due to 
hyperglycemia. In embryonic sensory neurons, treatment of hyperglycemia also induced 
depolarization of the mitochondrial Δψ [179]. In neurons, a loss of neurotrophic support 
induced the translocation of proapoptotic members of the Bcl-2 family of proteins, such as 
Bim and Bax, to the mitochondrial outer membrane causing mitochondrial membrane 
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depolarization and cytochrome c release [207-209]. In STZ-diabetic rats, impaired 
mitochondrial function was associated with reduced Bcl-2 expression [194]. In SCs 
exposed to high glucose, the resulting degeneration was linked to impaired functioning of 
Bcl-x [210].  
According to the chemiosmotic theory [206], ADP-to-ATP turnover rate is 
determined by the mitochondrial Δψ. Proton leak, opening of the mitochondrial 
permeability transition pore (MPTP), fatty acids interacting with mitochondrial proteins, 
or disruption of the inner membrane can cause mitochondrial Δψ loss [211, 212]. 
Mitochondrial ΔΨ potential can be measured by radioisotope, voltammetry or fluorimetry 
[213], based on the Nernstian equilibrium distribution of lipophilic cations [214]. In 
mitochondria, these cations accumulate inside negatively charged mitochondrial matrix 
binding with lipids and proteins to aggregate and even shift spectra [215-218]. Particular 
fluorophores that enter mitochondria can be used to determine potentials conveniently. 
Mitochondrial Δψ can be measured in isolated mitochondria or intact cells with various 
mitochondria-targeted potential-sensitive fluorescent compounds, such as 
methyltriphenylphosphonium (TPMP), tetraphenylphosphonium (TPP) or 
tetramethylrhodamine methyl ester (TMRM) [213, 219].  
1.4.3 Diabetes Impairs Mitochondrial Bioenergetics and Biogenesis 
In the mitochondrial respiratory chain, NADH coenzyme Q reductase (Complex I) 
receives electrons from the Krebs cycle electron carrier NADH, and passes them to 
coenzyme Q (ubiquinone), which also receives electrons from succinate dehydrogenase 
(complex II). Coenzyme Q passes electrons to cytochrome bc1 complex (complex III), 
which passes them to cytochrome c (Cyt c). Cyt c passes electrons to cytochrome c oxidase 
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(Complex IV), which uses the electrons to reduce oxygen into water. During this electron 
transport process, hydrogen ions are transported into the transmembrane area. This 
mitochondrial membrane potential allows the formation of ATP by ATP synthase with 
hydrogen ions flowing back into the matrix through the F0 component of ATP synthase. 
This reverse flux releases free energy generated during electron carriers (NAD+ and Q) 
oxidation driving ATP synthesis, catalyzed by the F1 component of ATP synthase [220]. 
Mitochondria respiration, known as aerobic respiration, is an oxygen-dependent 
process for ATP production. Thus, oxygen consumption of mitochondria is often used to 
evaluate mitochondrial bioenergetics. Oxygen consumption rate (OCR) can be assessed in 
whole cells or isolated mitochondria by measuring the decrease of O2 in the medium. OCR 
can be widely used to study mitochondrial function by adding various of mitochondrial 
respiratory inhibitors, ATP synthase activators or both [221].  
The basal OCR reflects coupled mitochondrial respiration as well as uncoupled 
consumption of oxygen forming ROS at mitochondrial and non-mitochondrial enzymatic 
sites. Coupled and uncoupled respiration can be distinguished by examining the effects of 
oligomycin, which is an ATP synthase inhibitor. Maximal oxygen consumption rate, 
provoked by addition of a mitochondrial uncoupling agent such as carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone (FCCP), provides an index of maximal energetic 
capacity. FCCP is protonophore and promotes the transport of hydrogen ions into 
transmembrane areas before they can be used for ATP generation. Since the rate of electron 
transport is limited by the MMP, dissipation of the MMP by FCCP removes the 
electrochemical gradient allowing electron transport to occur at its maximal rate and 
increasing OCR. The increase in OCR induced by FCCP is referred to as the Maximal 
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respiratory capacity (MRC) and this assesses the functional integrity of respiratory chain 
once electron transfer is no longer constrained by the proton gradient. Spare respiratory 
capacity (SRC) is the difference between MRC and basal respiration and reflects the 
energetic reserve that is available to cells to respond to stress [222, 223]. Diabetes often 
decreases both MRC and SRC indicating a decline in overall mitochondrial bioenergetics.  
MRC, SRC and mitochondrial oxidative phosphorylation protein expression were 
reduced in cultured sensory neurons from diabetic compared to non-diabetic animals [224-
226]. In addition, in cultured diabetic sensory neurons, there was an abnormal 
mitochondrial fission-fusion equilibrium, resulting in small mitochondria fragmentation 
[185, 227]. In vitro hyperglycemic stress to sensory neurons can also reduce mitochondrial 
protein translation and decrease mitochondrial OCR [228]. In peripheral nerves, DRG 
sensory neurons are not the only target of hyperglycemic stress. In SCs cultured under 
hyperglycemic conditions, there was reduced coupled mitochondrial respiration efficiency 
and altered mitochondrial protein expression [229]. Hyperglycemia-induced mitochondrial 
dysfunction in SCs may additionally contribute to sensory neuron dysfunction and mediate 
DPN development in diabetic animals and humans. 
Disruption of mitochondrial biogenesis has also been suggested to cause reduced 
mitochondrial number, depolarized mitochondrial Δψ and reduced oxidative 
phosphorylation capacity in diabetes.  
 Mitochondrial biogenesis and function can be partially modulated, through the AMP-
activated protein kinase (AMPK), sirtuin (SIRT), and peroxisome proliferator-activated 
receptor-γ coactivator α (PGC-1α) signaling axis that senses cellular requirements for 
energy [186, 230, 231]. These factors regulate the expression of mitochondrial replication 
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and oxidative phosphorylation genes [232]. PGC-1α activity is enhanced by AMPK 
phosphorylation and SIRT1 deacetylation. Energy expenditure, such as caloric intake and 
exercise reduction, leads to an increase in the ratio of AMP to ATP, which activates AMPK 
[231, 233]. In turn, this increases PGC-1α transcription and phosphorylation. Caloric 
restriction or exercise also increased NAD+ relative to NADH and activates the NAD+-
dependent histone deacetylase, SIRT1. SIRT1 enhances PGC-1α by deacetylation at 
specific lysine residues [234]. AMPK signaling and PGC-1α expression were depressed in 
DRG sensory neurons in animal models of Type 1 or Type 2 diabetes [235]. This means 
under diabetic conditions within the perikarya, the high intracellular glucose concentration 
triggers the down-regulation of the AMPK/SIRT/PGC-1α pathway [236]. 
PGC-1α is mainly expressed in tissues with high oxidative demands such as heart, liver, 
brain, skeletal muscle and brown adipose [237]. PGC-1α activation mediates the regulation 
of gluconeogenesis, glycolysis, lipogenesis, peroxisomal and mitochondrial fatty acid 
oxidation, and mitochondrial respiration efficiency [238-240]. Over-expression of PGC-
1α induces an increase in the number and function of mitochondrial [241]. In contrast, the 
absence of PGC-1α results in abnormal glucose homeostasis and decreased mitochondrial 
function [242].  
In DRG sensory neuron from STZ-induced diabetic mice, the protein expression of p-
AMPK and PGC-1α were significantly decreased by 8 weeks of diabetes [230]. The 
decreased activation of AMPK and PGC1-α is associated with the down-regulation of a 
series of mitochondrial biogenesis proteins, including oxidative phosphorylation enzymes 
(NDUFS3, COX IV), the Kreb’s cycle enzyme (citrate synthase) and the mitochondrial 
ROS scavenger MnSOD [186, 230, 243]. This down-regulated AMPK/SIRT/PGC-1α 
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pathway correlated with mitochondrial dysfunction in sensory neurons during DPN 
development [230].  
Unfortunately, all drug candidates for DPN so far, showed modest efficacy or adverse 
side effects in clinical trials. Identification of novel therapeutic targets for DPN is urgent. 
Instead of focusing on only one target, our group proposes that through the induction of 
cytoprotective chaperones, DPN development can be delayed or reversed. 
1.5 Heat Shock Proteins 
Heat shock proteins (Hsps) are molecular chaperones that help cells through stressful 
conditions. Hsps are important for the folding of newly synthesized proteins and refolding 
denatured ones [244]. They function constitutively to stabilize and traffic nascent peptides 
during cell growth, prevent protein aggregation, or target improperly folded proteins to 
specific pathways for degradation. Hsps can function as housekeeping proteins or can also 
be induced by environmental, physical and chemical stresses, such as UV irradiation, heat 
or cytotoxic drugs [245]. Under stressful conditions such as heat shock or hypoxia, 
increased expression of Hsps protects the cell by stabilizing unfolded or misfolded peptides, 
allowing the cell to repair or re-synthesize damaged proteins. They also aid the transport 
of proteins and proteolytic degradation of damaged proteins [246].  
Functional proteins within cells are usually in a fully folded form. However, during 
protein biogenesis or translocation, proteins can become temporarily unfolded. During this 
conformational change, regions buried within the mature form may be exposed and interact 
with other proteins causing unwanted aggregation. To prevent this unwanted aggregation, 
Hsps can bind with interactive surfaces and facilitate the folding of nascent or unfolded 
polypeptides. As heat shock and other stress conditions could cause cellular proteins to 
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unfold partially, the ability of Hsps to protect cells from stress is a key feature of molecular 
chaperones [247, 248]. 
Hsps play an important role in neurodegenerative diseases, cancer and metabolic 
disease. Heat shock can induce Hsp expression through heat shock factor 1 (HSF1) to 
protect cells against stressful conditions [249]. However, the heat shock response is 
hampered in diabetes, which is characterized by reduced induction of endogenous 
protective responses [250].  
1.5.1 Heat Shock Protein Classification 
        Hsps can be classified into five major families based on molecular weight, including 
Hsp100, Hsp90, Hsp70, Hsp60 and small heat shock proteins; Hsp90, Hsp70 and Hsp60 
are the most abundant Hsps [251]. 
Hsp90 
The Hsp90 family contains four isoforms, including inducible cytosolic Hsp90α, 
constitutive cytosolic Hsp90β, endoplasmic reticulum localized glucose regulated protein 
94 (Grp94), and mitochondrial tumor necrosis factor receptor type 1-associated protein 
(TRAP1). Hsp90 is a dimeric protein consisting of three domains: an N-terminal ATP-
binding domain, a middle region, and a C-terminal domain involved in homodimerization 
[252, 253]. Although the ATPase activity of Hsp90 is weak, ATP binding and hydrolysis 
is crucial to chaperone function [254].  
Hsp90 normally binds to and suppresses HSF1. Denatured proteins can initiate the 
heat shock response by binding with Hsp90, which results in the dissociation of Hsp90 
from HSF1. The dissociation of Hsp90 from HSF1 can lead to the phosphorylation of HSF1, 
which leads to HSF1 activation. The activated HSF1 forms a homo-trimer that binds to the 
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promoter of Hsp70 and other chaperone genes to stimulate their transcription [255, 256]. 
This leads to an increase in Hsp70 mRNA and protein levels in the stressed cells. The 
induction of Hsp70 upon proteotoxic stress aids the refolding and clearance of mis-folded 
or damaged proteins.  
Hsp70 
Hsp70 assists in the folding of newly synthesized proteins, refolding of mis-folded 
or aggregated proteins, transporting proteins across membranes and controlling regulatory 
proteins [257-259]. Hsp70 is composed of three major domains: the ATPase N-terminal 
domain, the substrate binding domain and the C-terminal domain that provides a lid for 
substrate binding domain [260]. Co-chaperones including Hsp40, Hsp70-interacting 
protein (HIP), Hsp70-Hsp90 organizing protein (HOP) and Bag-1 can regulate Hsp70 
activity [261]. Hsp40 delivers the client protein to Hsp70 and stimulates ATP hydrolysis 
[262]. HIP assists Hsp70 in retaining the client protein [262] while Bag-1 and HspBP1 
increase the rate of ADP dissociation and the release of the client protein [263, 264].  
The Hsp70 family is composed of 13 proteins [265]. The most widely studied forms 
include the constitutively expressed Hsc70, inducible Hsp72 (Hsp70 in mouse), the 
endoplasmic reticulum localized Grp78 (BiP), and the mitochondrial Grp75 (mtHsp70). 
Cytoplasmic isoforms include the constitutively expressed Hsc70 and the stress-inducible 
Hsp72 [266]. Hsc70 is consistently expressed in most tissues and is considered to be the 
major isoform involved in the housekeeping functions associated with the Hsp70 family. 
In comparison, Hsp72 is present only in low amounts in unstressed cells but its expression 
is rapidly increased in response to stress through the transcriptional activation of the gene 
encoding Hsp72 by HSF1 [259]. Hsp70 can bind to denatured proteins to restore the tertiary 
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structure and enzymatic activity of proteins in a cycle that is driven by ATP hydrolysis. 
Mitochondrial targeted proteins can also bind to Hsp70 before being transported into 
mitochondria. Cytoplasmic Hsp70 helps the proteins to remain a linear state of the protein 
chain rather than folding, so that the protein can penetrate through the mitochondrial 
membrane. Once across the mitochondrial membrane, mtHsp70 draws the protein chain 
into the mitochondrial matrix by consuming ATP [267].  
Hsp70 participates in two pathways of disposing wrongly folded proteins: namely 
proteasomal and lysosomal degradation. Ubiquitiantion labels proteins for degradation by 
the 26S proteasome. Protein ubiquitination requires ubiquitin-activating enzyme E1 
binding to ubiquitin and transfer to the enzyme-carrier E2. E2 can associate with E3 
ubiquitin ligase which delivers ubiquitin to the protein designated for degradation. After 
these three steps, the proteasome recognizes and degrade the ubiquitin labelled proteins. 
The ubiquitin-proteasome system needs Hsp70 and Hsp40 for degradation of short-lived, 
mutant or aged proteins [268]. 
Several studies have reported that expression of Hsp70 can reduce cellular toxicity in 
several neurodegenerative aggregation disease models. In Alzheimer's disease (AD) 
models, increased Hsp70 can increase amyloid precursor protein (APP) clearance, inhibit 
Aβ aggregation and reduce Aβ toxicity on neurons [269-271]. Hsp70 also promotes tau 
solubility and facilitates tau binding to microtubules [272]. In Huntington’s disease (HD), 
Hsp70 and its cochaperone Hsp40 can suppress the assembly of the huntingtin protein into 
spherical and annular polyglutamine oligomers [273]. 
Hsp60 & Small Hsps 
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Unlike Hsp70, Hsp60 is the only member in Hsp60 family. It can ensure the correct 
folding of newly synthesized or imported mitochondrial proteins, and may also promote 
the refolding of mis-folded proteins generated under stress [274]. It is a mitochondrial 
chaperonin that is responsible for the transport of linear proteins from the cytoplasm into 
the mitochondrial matrix for refolding [275]. The capacity of Hsp60 to stabilize 
mitochondrial proteins, promote mitochondrial protein biosynthesis and prevent induction 
of mitochondrial apoptosis seems to be crucial for its cytoprotective functions [275, 276]. 
In the cytoplasm, Hsp60 plays a key role in preventing apoptosis. Hsp60 may inhibit 
caspase-3 or facilitate the maturation of pro-caspase-3 to its active form [277].  
Small Hsps (sHsps) also exhibit chaperone-like activity in preventing unwanted 
aggregation of target proteins, ensuring the correct folding and refolding of denatured ones 
alone or in cooperation with other ATP-dependent chaperones [278].  
1.5.2 Hsp90 Inhibitors Development 
N-terminal Inhibitors 
     Numerous Hsp90 N-terminal inhibitors have been designed to target the ATP-binding 
pocket. These compounds block the Hsp90 chaperone activity and cause the release of the 
premature, unfolded client proteins [279].  
Geldanamycin (GM) (Fig.1.5.2.1) was discovered as the first Hsp90 N-terminal 
inhibitor. It binds in the ATP/ADP pocket in the N-terminal domain of Hsp90 and inhibits 
the Hsp90 chaperone cycle [280]. GM induced a dose-dependent increase of Hsp70 in an 
AD cell model, as well as in rat primary cortical neurons [272]. In cells exposed to GM, 
there was accumulation of premature Hsp90 client protein complexes leading to 
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recruitment of E3 ubiquitin ligases that target Hsp90 clients for degradation in the 
proteasome [281, 282]. However, GM has been proved to be too toxic for human use [283]. 
17-AAG (Tanespimycin) is a GM derivative with Hsp90 inhibitory activity but with 
less toxicity. However, minimal efficacy against melanoma, renal, and prostate cancers 
was observed in the Phase 1 trials and no patients in these trials achieved either a partial or 
complete response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 
[284]. The drug development was halted after Phase 2 clinical trials. 
 
Figure 1.5.2.1: Chemical structures of Hsp90 N-terminal inhibitors 
C-terminal Inhibitors 
       In contrast to N-terminal inhibitors, C-terminal inhibitors prevent formation of the 
Hsp90 homodimer and prohibit binding with client proteins [285]. Novobiocin was the first 
Hsp90 C-teriminal inhibitor that was described. Novobiocin (Fig.1.5.2.2) is composed of 
three distinct parts, including the benzamide side chain, the coumarin core and the noviose 
sugar [286]. The benzamide side chain binds to the co-chaperone Aha1 and prevents its 
interaction with Hsp90, while the noviose sugar is critical for interacting with C-terminal 
domain of Hsp90 [287]. However, novobiocin was reported to bind weakly to the Hsp90 
C-terminal nucleotide-binding site and induce degradation of Hsp90 client proteins. 
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Subsequently, a series of novobiocin analogues were synthesized to improve its Hsp90 
inhibitory activity and reduce its cytotoxicity [288]. 
 
Figure 1.5.2.2: Chemical structures of Hsp90 C-terminal inhibitors 
KU-32 and KU-596 were developed as novobiocin-based Hsp90 C-terminal 
inhibitors. The noviose sugar in KU-32 and KU-596 still allows their binding to Hsp90α 
[289]. These C-terminal inhibitors can segregate induction of the cytoprotective heat shock 
response from cytotoxic client protein degradation due to the presence of the acetamide 
side chain off the coumarin instead of a benzamide or biaryl ring system [290-294]. KU-
32 was found to protect against neuronal glucotoxicity and to reverse DPN development in 
mice [295, 296]. KU-596 was developed as the next generation of novologues, by replacing 
the coumarin core of KU-32 with a biphenyl ring system and flexible side chain. It has 
stronger Hsp70 induction ability and enhanced neuroprotective activity against 
glucotoxicity in sensory neurons [289, 297]. KU-32 and KU-596 can improve 
mitochondrial bioenergetics in diabetic sensory neurons, and reverse DPN development 
[298, 299].  
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1.5.3 Heat Shock Proteins in DPN 
Both Type 1 and Type 2 diabetic patients are at high risk of developing macrovascular 
and microvascular complications. In diabetes, various types of stresses, including 
dyslipidemia, modification of proteins and lipids, ischemia, hypoxia, apoptosis and 
oxidative stress, can overwhelm defense system to cause cellular injury [300, 301]. These 
hyperglycemic stresses can impair protein folding, decrease refolding and induce unwanted 
aggregation [302]. Hsps may play a crucial role in diabetes by counteracting protein 
denaturation and facilitating endogenous cellular repair mechanisms. However, 
hyperglycemic stress may interfere with Hsps synthesis and/or action, to exacerbate 
diabetic complications [303-305]. 
In Type 2 diabetes patients with insulin resistance, there were lower levels of Hsp72 
mRNA in skeletal muscle [305, 306]. Decreased Hsp72 mRNA levels in skeletal muscle 
tightly correlated with a poor glucose disposal rate, decreased mitochondrial activity and 
oxidative capacity [306]. In Type 1 diabetes patients with polyneuropathy, Hsp72 levels in 
peripheral blood leukocytes were considerably lower than in healthy people [307]. This 
poor Hsp70 mRNA expression correlated with increased JNK activity [308]. A genetic 
assessment in diabetic patients identified Hsp70 gene polymorphisms are associated with 
an increased severity of diabetic foot ulceration, necessity for amputation and longer 
duration of hospitalization [309].  
Overexpression of Hsp72 by transgenic and pharmacologic methods can prevent diet 
or obesity induced hyperglycemia, hyperinsulinemia, impaired glucose tolerance and 
insulin resistance. These indicate that Hsp72 plays an essential role in preventing insulin 
resistance and inflammation in obesity [308]. In addition, long-term hyperglycemia in 
49 
 
diabetes also reduced the HSF-1 mediated heat shock response in heart and muscle [310, 
311]. Pharmacological induction of Hsp72 by a hydroxylamine derivative, BGP-15, 
activated HSF1 and improved insulin-sensitivity in early clinical trials [312]. Bimoclomol 
can elevate various Hsps levels, typically Hsp72. In STZ-induced Type-1 diabetic rats, 
bimoclomol can improve motor and sensory nerve conduction velocity (NCV) deficits as 
well as the ischemic conduction failure in sciatic nerve by anti-ischemic and chaperone-
inducing properties [313]. Arimoclomol is another hydroxylamine derivative that is 
currently under clinical development, with a 4 time longer half life time than bimoclomol. 
Arimoclomol can dose-dependently improve both the motor and sensory functions in DPN, 
with more pronounced effects than bimoclomol [314, 315]. Physical exercise can also 
increase Hsp72 expression and help protect against cell injury and repair damaged nerves 
in STZ-induced diabetic rats [316].  
The novobiocin-derived Hsp90 C-terminal inhibitor KU-32 reversed diabetic 
mechanical and thermal sensory hypoalgesia along with improving motor and sensory 
NCV in STZ-induced diabetic mice. KU-32 also prevented the loss of unmyelinated intra-
epidermal nerve fibers innervation in diabetic mice to reverse DPN development [226, 295]. 
However, KU-32 did not change serum glucose or insulin levels, indicating the drug effect 
is more directly on peripheral nerves [295].  
In vivo KU-32 treatment improved mtBE in both the Type 1 and Type 2 models, and 
this correlated with a reversal of DPN symptoms [299]. Hsp70 is necessary for KU-32 to 
reverse DPN development since the drug had no effect on reversing DPN sensory 
hypoalgesia in diabetic Hsp70 knockout (KO) - (Hsp70.1 and 70.3) mice. This is also 
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associated with the loss of effect on improving mtBE deficits in diabetic Hsp70 KO sensory 
neurons [295, 299]. 
Hyperglycemia reduced the translation of a variety of mitochondrial proteins, 
including MnSOD, which is associated with an increase in mitochondrial superoxide levels 
and a decrease in mtBE. KU-32 increased the translation of several cytosolic and 
mitochondrial chaperones, components of the mitochondrial respiration chain and MnSOD 
in hyperglycemically stressed neurons. These changes correlated with decreased 
mitochondrial superoxide levels and increased mitochondrial respiratory capacity. These 
data indicate that KU-32 may improve the sensory defects of DPN by improving 
mitochondrial function and enhancing chaperone levels [228]. However, the mechanism 
by which KU-32 can improve mtBE in diabetic sensory neurons has not been determined. 
KU-596 is the next generation of noviosylated analogs that has stronger Hsp70 
induction and neuroprotective ability. In vivo treatment of 2–20 mg/kg KU-596 improved 
hypoalgesia and mtBE deficits of sensory neurons in STZ-induced Type 1 diabetic mice in 
a dose-dependent manner. Similar to KU-32, the drug effect is dependent on Hsp70 since 
KU-596 could not improve these neuropathic deficits in diabetic Hsp70 KO mice [298]. 
The efficacy of KU-32 and KU-596 in reversing several indices of DPN strongly 
supports that modulating molecular chaperones might be a promising method to prevent 
nerve injury in DPN. Although DPN is primarily a metabolic disease, hyperglycemic stress 
can increase oxidative damage to proteins, impair protein folding, decrease refolding or 
induce protein aggregation [186, 302]. In this regard, increasing protective chaperones in 
peripheral nerves may provide a level of quality control by enhancing protein folding or 
refolding. Thus, modulating chaperone is beneficial to interfere with the progression of 
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diabetes and its complications. As reported in numerous studies from our own group and 
other groups, prolonged diabetes can decrease mitochondrial respiratory chain activity in 
adult sensory neurons [194, 226, 317]. The decrease in SRC means diabetic neurons are 
more susceptible to stress because they cannot increase energy supply sufficiently to match 
the demand [221, 318]. Previous studies from our lab have demonstrated that 
pharmacologically modulating Hsp70 by KU-32 or KU-596, has a beneficial effect on 
mtBE and improves SRC [226, 298]. Thus, increasing the expression of mitochondrial 
chaperones might protect against mitochondrial dysfunction in diabetic sensory neurons.  
Though our previous publication has suggested in vivo treatment of next generation 
novologue KU-596 can improve mitochondrial bioenergetics in diabetic sensory neurons 
and reverse DPN in Hsp70 dependent manner, we have not identified the mechanism by 
which KU-596 improves mitochondrial function in diabetic sensory neurons. 
Understanding the mechanistic contributions of Hsp70 on improving mtBE will advance 
novologue development in reversing DPN. 
In vivo treatment of KU-596 can improve mtBE and modulate inflammatory response 
in diabetic sensory neurons. Since there are many factors in vivo that can mediate the drug 
effect on DPN, it is hard to identify if the drug directly or indirectly improving sensory 
neuron mtBE after in vivo treatment. For example, axons of sensory neurons are wrapped 
with SCs, and SCs may also mediate the drug effect since the drug needs to enter the myelin 
first and get into the axon. To more directly assess the ability of KU-596 to improve 
neuronal bioenergetics, the focus of these studies is to use an ex vivo approach. In this 
model, sensory neurons are isolated from non-diabetic and diabetic mice and subsequently 
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treated with KU-596, to identify direct drug effect on sensory neuron bioenergetics and 
oxidative stress.  
In this current study, we sought to determine if Hsp70 enhances mtBE and decreases 
oxidative stress in diabetic sensory neurons. In order to determine the cause and effect 
relationship between mtBE and oxidative stress, we knocked down MnSOD by shRNA to 
increase oxidative stress in mitochondria and determine if KU-596 can decrease the 
oxidative stress and improve mitochondrial function. Our goal is to identify whether 




Chapter 2. KU-596 Improves Mitochondrial Bioenergetics and Decreases 
Oxidative Stress in Diabetic Sensory Neurons via Hsp70 
2.1 Introduction 
Diabetes affected about 415 million adults worldwide in 2015 and about 50-60 percent 
of these patients are likely to develop diabetic peripheral neuropathy (DPN) [3, 319]. DPN 
is one of the most prevalent complications of diabetes and manifests as a distal, symmetric 
and sensorimotor neuropathy that causes positive (sharp pain) and negative (numbness, 
injury insensitivity) symptoms. Insensate DPN is a main cause of foot ulceration, infection 
and non-traumatic amputation as the loss of feeling often leads to unnoticed tissue injuries. 
Unfortunately, other than glycemic control, there is still no approved drugs to help improve 
nerve function and resolve insensate DPN [67, 320].  
The mechanistic pathogenesis of DPN is complex but the developing consensus is that 
sustained hyperglycemia drives numerous secondary biochemical changes that contribute 
to a progressive decline in sensory neuron function and the loss of peripheral innervation 
that characterizes moderate to severe cases of DPN. Though accumulation of advanced 
glycated end products, abnormal protein kinase C activity, increased oxidative stress, 
mitochondrial dysfunction and increased flux of glucose through polyol and hexosamine 
pathways are known to contribute to the development of DPN [321], compounds targeting 
these pathways have shown little efficacy in clinical trials [322]. However, targeting a 
single pathway or protein considered to contribute to disease progression may not be an 
effective approach to manage complex, chronic neurodegenerative diseases. Alternatively, 
it may prove sufficiently beneficial to pharmacologically enhance the activity of 
endogenous neuroprotective pathways to help neurons more effectively tolerate recurring 
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hyperglycemic stress, which may ameliorate the development of DPN or reverse pre-
existing insensate symptoms [323]. In this regard, we have provided extensive proof-of-
concept that pharmacologic modulation of neuroprotective heat shock proteins may 
provide a novel, safe and effective approach toward the therapeutic management of DPN 
[290, 295, 298, 299, 324, 325]. 
Heat shock proteins (HSPs), such as Hsp70 and Hsp90 function as molecular 
chaperones that are important for folding newly synthesized proteins and for refolding or 
clearing damaged/denatured proteins [326, 327]. Hsp90 contains a C-terminal domain that 
is essential for forming a functional Hsp90 homodimer and an intrinsic N-terminal ATPase 
activity which, in conjunction with a cohort of co-chaperones, directs the folding of “client” 
proteins into their biologically active conformations [328-330]. However, Hsp90 also 
serves another important biologic role since it is a direct regulator of the cellular heat shock 
response (HSR). Hsp90 binds to heat shock factor 1 and suppresses its transactivating 
capacity [331, 332]. Upon exposure to proteotoxic stress or binding of small molecules, 
conformational changes in Hsp90 disrupt its interaction with HSF1 and lead to the 
transcriptional induction of cytoprotective proteins, such as Hsp70 [331].  
Though numerous small molecules that function as N-terminal Hsp90 inhibitors have 
been developed to treat cancer [333], small molecules that interact with the C-terminal of 
Hsp90 show strong promise as therapeutic candidates to treat diabetic neurodegeneration 
[290]. Novobiocin was identified as the first ligand to interact with the C-terminal of Hsp90 
[334] and the development of diverse libraries of novobiocin derivatives have identified 
KU-596 as a noviosylated fluoro-biphenyl ethylacetamide “novologue” [335] that 
demonstrates considerable efficacy in improving insensate DPN [298]. Treating diabetic 
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mice with KU-596 improved sensory hypoalgesia and this required Hsp70 since the drug 
could not improve sensory nerve function in diabetic Hsp70 knockout (KO) mice. 
Moreover, improved neuronal function following KU-596 therapy correlated with 
enhanced mitochondrial bioenergetics (mtBE) and a decrease in markers of oxidative stress 
and inflammation in diabetic dorsal root ganglia (DRG) [298]. However, the mechanism 
by which KU-596 improves mtBE in diabetic sensory neurons remains to be determined. 
 Mitochondrial dysfunction is a major pathogenic contributor to DPN and reduced 
respiratory chain activity is observed in sensory neurons [236, 336, 337]. Since an earlier 
generation of novobiocin derivatives decreased superoxide levels and increased the 
expression of Mn superoxide dismutase (MnSOD) in hyperglycemically stressed 
embryonic sensory neurons [338], these data raised the possibility that novologues may 
require MnSOD to improve mtBE. 
Though in vivo treatment of KU-596 improved sensory neuron mtBE and decreased 
genetic indicators of oxidative stress and inflammation in diabetic DRG [298], it was 
unclear if this may be a direct or indirect effect of the drug. To determine if KU-596 can 
directly improve mtBE and whether this is related to changes in oxidative stress, sensory 
neurons were isolated from diabetic mice who had developed insensate DPN and were 
treated ex vivo with KU-596. By manipulating glucose conditions and downregulating the 
expression of MnSOD, the current study provides strong evidence that KU-596 can directly 
improve mBE and that this is related to a decrease in glucose-induced superoxide 
production.  





 C57Bl/6N Hsd wild type (WT) mice were obtained from Harlan Laboratories and the 
Hsp70.1/70.3 double knockout mice on a C57Bl/6 background (Hsp70 KO) mice were 
obtained from the Mutant Mouse Resource and Research Center.  Experimental animals 
were generated by in-house breeding and were maintained on a 12-hour light/dark cycle 
with ad libitum access to water and 7022 NIH-07 rodent chow (5.2% fat). All animal 
procedures were performed in accordance with protocols approved by the Institutional 
Animal Care and Use Committee and in compliance with standards and regulations for the 
care and use of laboratory rodents set by the National Institutes of Health. 
2.2.1.2 Reagents 
Table 2.2.1: List of major reagents used in this study 
Name Company Catalog Number 
Streptozotocin (STZ) Sigma-Aldrich 572201 




Rotenone  Sigma-Aldrich R8875 
Antimycin A Sigma-Aldrich A8674 
Poly(DL)ornithine Sigma-Aldrich P8638 
Collagenase Type IV Life Technologies 17104-019 
Laminin Corning 354232 
Percoll Sigma-Aldrich P1644 
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mitoTracker Deep red Fisher M22426 
mitoSOX Fisher M36008 
mito-TEMPO-H Enzo Life Sciences ALX-430-171-
M005 
 
Synthesis of KU-596 
KU-596, N-(2-(5-(((3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-
pyran-2-yl)oxy)-3’-fluoro-[1,1’-biphenyl]-2-yl)ethyl)-acetamide, was synthesized and 
structural purity (>95%) verified as described previously [297]. 
2.2.2 Methods 
2.2.2.1 Induction of diabetes  
Eight-week-old male and female WT and Hsp70 KO mice were randomly assigned to 
either the non-diabetic or diabetic group. Mice were rendered diabetic with an 
intraperitoneal injection of 100 mg/kg streptozotocin (STZ) freshly prepared in 50 mM 
sodium citrate, pH 4.5 and given over two consecutive days. Control mice were treated 
similarly but received only the vehicle. One week after the second injection, mice were 
fasted for 6 hrs and those with a fasting blood glucose ≥ 290 mg/dl were deemed diabetic 
[299].  
2.2.2.2 Mechanical and Thermal Sensitivity Assessments 
To monitor the development of diabetic neuropathy, the onset of a mechanical and 
thermal hypoalgesia was determined over 14 weeks after the induction of diabetes. This 
time frame was chosen as our previous work found that this duration of diabetes was 
sufficient to promote mitochondrial dysfunction in sensory neurons [298, 299]. Mechanical 
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sensitivity was assessed using a Dynamic Plantar Aesthesiometer (Stoelting Inc.) fitted 
with a stiff monofilament that was applied to the plantar surface at an upward force of 8g. 
Thermal sensitivity was assessed by paw withdrawal latency to a ramping, focal heat using 
a Hargreaves Analgesiometer (Stoelting Inc.) [299]. Responses from each animal were 
measured four times on alternate feet and averaged.  
2.2.2.3 Adult DRG Sensory Neuron Isolation 
After 12-14 weeks of diabetes, adult sensory neurons were isolated from the non-
diabetic and diabetic WT or Hsp70 KO mice as previously described [226, 299]. Mice were 
euthanized via gradual CO2 asphyxiation, the spinal column dissected and the L4–L6 DRG 
collected from 6 - 8 mice in each group. Connective tissue was removed and the ganglia 
were placed in 1 ml serum-free Ham’s F10 medium (Corning, #10-070-CV). The trimmed 
ganglia were dissociated by incubating in 1 ml of 1.25% collagenase for 45 min at 37 °C, 
and subsequent addition of 1 ml 2% trypsin for 30 min at 37 °C. Digested cells were 
centrifuged at 1000 × g for 5 min at 4oC and the pellet was further dissociated by trituration 
with a fire polished glass pipette in F10 medium. The cell suspension was overlain onto a 
10 ml gradient of sterile iso-osmotic Percoll (0.9 ml of 10× PBS, 6.5 ml H2O, 2.6 ml Percoll) 
and centrifuged at 800 × g for 20 min at 4oC to remove all cell debris and myelin fragments. 
The cell pellet was re-suspended in fresh F10 medium with N2 supplement (Invitrogen, 
Carlsbad CA). Isolated neurons were plated at a density of 5 × 103 cells/well in F10 medium 
with N2 supplement on 96 well plates that had been coated overnight with 0.1 mg/ml poly-
DL-ornithine and 2 μg/ml laminin (3 hrs) [299, 339]. After plating, the adult sensory 
neurons were treated with 1μM KU-596 or 0.01% DMSO overnight (~16 hrs) and 
subsequently incubated in F10 medium containing basal glucose (6.1mM) or 26.1 mM 
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glucose for an additional 24 hrs. The cells were then used to assess mtBE or superoxide 
production as shown in Fig. 2.2.2.1.  
 
Figure 2.2.2.1: Time-course of this current study 
2.2.2.4 Mitochondrial Bioenergetics (mtBE) Assessment 
 Sensory neuron mtBE were analyzed using a Seahorse XF96 Analyzer (Seahorse 
Biosciences, Billerica, MA). After incubation in basal or hyperglycemic medium, the cells 
were placed in bicarbonate free DMEM containing 5.5mM glucose plus 1 mM pyruvate 
and incubated for 1 hr at 37oC. The plate was then introduced into the Seahorse Analyzer 
using a 3 minute mix cycle to oxygenate the medium followed by a 4 min measurement of 
the Oxygen Consumption Rate (OCR). The initial four OCR rates provide a measure of 
basal respiration prior to assessing mitochondrial dysfunction using various respiratory 
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chain inhibitors. The portion of basal OCR that is coupled to ATP synthesis was estimated 
by the decrease in OCR followed by the addition of 1 μg/ml oligomycin, an ATP synthase 
inhibitor. Residual OCR remaining after oligomycin treatment is from uncoupled 
respiration (proton leak). Next, Maximal Respiratory Capacity (MRC) was assessed 
following dissipation of the proton gradient across the inner mitochondrial membrane with 
1 μM of the protonophore FCCP. Non-mitochondrial respiration was then assessed by co-
injection of 1μM rotenone + 1μM antimycin A [298, 299].  
2.2.2.5 MitoSOX Staining 
Superoxide levels were measured in some experiments by Mito SOX Red staining in 
black 96-well plates. After incubation in basal or hyperglycemic medium, MitoTracker 
Deep Red (300 nM) and MitoSOX Red (400 nM) were added to each well and the cells 
incubated for 15 min. After washing, the cells were imaged using an Olympus 3I Spinning 
Disk confocal microscope using excitation/emission wavelengths of 488/573 nm (MitoSox 
Red) and 644/665 nm (MitoTracker Deep Red). Fluorescence density of the red and deep 
red signals of 35 - 50 cells per treatment was quantified using Image J analysis software 
[228]. 
2.2.2.6 Knockdown of MnSOD Expression by shRNA and Superoxide Assessment 
by Electron Paramagnetic Resonance (EPR) Spectroscopy 
Recombinant adenoviruses expressing shRNA targeting mouse MnSOD (Ad-GFP-
U6-mSOD2-shRNA, #shADV-272843) or scrambled shRNA with GFP (Ad-GFP-U6-
scrambled-shRNA, #1122) were purchased from Vector BioLabs (Malvern, PA).  




The sequence of mouse MnSOD shRNA is: 
CCGG-GAGGCTATCAAGCGTGACTTTCTCGAGAAAGTCACGCTTGATAGCCTC-TTTTTTG 
To evaluate the silencing efficiency, sensory neurons were infected immediately after 
plating with either the scrambled shRNA or the mouse MnSOD shRNA for 48 h. Cell 
lysates were prepared and protein expression was evaluated by immunoblotting with a 
MnSOD polyclonal antibody (Millipore-Sigma, #06-984). 
Immediately after plating, the isolated sensory neurons were treated with vehicle or 
1μM KU-596 and infected with the scrambled shRNA or MnSOD shRNA adenoviruses 
(1:50) for 36 h. The cells were then incubated in basal glucose or 26.1 mM glucose for an 
additional 24 hr. During the final 4 hrs, the cells were incubated with 100 μM mitoTEMPO-
H (1-hydroxy-4-[2-triphenylphosphonio-acetamido]-2,2,6,6-tetramethylpiperidine). 
mitoTEMPO-H is a mitochondria-targeted antioxidant and is a specific spin trap for 
detecting mitochondrial superoxide [340]. The cells from 8 wells were pooled together, 
pelleted by brief centrifugation, re-suspended in 0.2 ml of fresh F-10 medium and frozen 
at -80 °C until use. When performing the EPR measurements, cells were introduced into a 
quartz tube and EPR was performed with a Bruker EMX plus EPR spectrometer (Billerica, 
MA, USA) using Bruker Xenon software. Settings for the spectrometer were the following: 
center field: 3480 G; Sweep width: 100 G; modulation amplitude: 1 G; and time constant, 
0.01 s [341, 342]. The cells were recovered from the cuvette and total protein determined 
using the microBCA assay with bovine serum albumin as the standard. 
2.2.2.7 Statistical Analysis: 
Student’s t test, one-way ANOVA, and multivariate-ANOVA were conducted for 
between-group comparison by Minitab Software and SAS. Post-hoc analysis using 
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Tukey’s test and Wilks' lambda test was applied to determine differences between 
treatments. All data are presented as mean ± SEM. 
2.3 Result 
2.3.1 Ex vivo Treatment of KU-596 Improves mtBE in Diabetic Sensory Neurons in 
an Hsp70 Dependent Manner 
2.3.1.1 Mouse Models of Diabetic Peripheral Neuropathy 
Diabetic mice were monitored for the development of DPN by assessing the onset 
of mechanical and thermal hypoalgesia. After 6 weeks of diabetes, both WT and Hsp70 
KO mice developed mechanical and sensory hypoalgesia by requiring more force or longer 
time to withdraw their hind paw in response to mechanical pain or thermal stimulation 
(Figs. 2.3.1.1.A-D). As we reported previously, the development of insensate DPN is 
consistent throughout the whole course of diabetes.  
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Figure 2.3.1.1 Mechanical and thermal hypoalgesia developed in C57Bl/6 mice over 
6 weeks of Type-1 Diabetes. 
Diabetes induced significant mechanical (A, C) and thermal hypoalgesia (B, D) in both 
WT (A, B) and Hsp70 KO (C, D) mice (*:p<0.05, vs time-matched non-diabetic mice 
with VEH). 
 
2.3.1.2 KU-596 Improves mtBE in WT Sensory Neurons under Both Normal and 
Hyperglycemic Conditions 
After 14 weeks, adult sensory neurons were isolated from L4 to L6 DRG of non-
diabetic and diabetic WT and Hsp70 KO mice since these ganglia provide the sensory 
axons of the peripheral nerves that are affected in DPN. The isolated neurons were 
maintained in F-10 medium which has a basal glucose (BG) concentration of 6.1mM. After 
isolation, the neurons were treated with vehicle (0.01% DMSO final concentration) or 1μM 
KU-596 overnight (~16 hr). The cells were then maintained for an additional 24 hrs in 
medium with BG or subjected to hyperglycemic (HG) stress by incubation in F-10 medium 
containing 26.1 mM glucose. The cells were then prepared for analysis of mtBE by 
Seahorse XF96 Analyzer as described in the Methods.  
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One advantage of this ex vivo cell culture model is that neurons from diabetic animals 
have developed metabolic changes due to chronic in vivo diabetes that cannot be adequately 
recapitulated using adult neurons that are only exposed to hyperglycemia and KU-596 in 
vitro. As shown previously [185], this ex vivo culture model may more accurately reflect 
the in vivo response of the neurons to further episodes of glucotoxic stress. 
Neurons isolated from the diabetic mice and maintained in BG had a significantly 
lower OCR, MRC and spare respiratory capacity (SRC) than neurons obtained from the 
non-diabetic mice (Figs. 2.3.1.2.A-D). Though 14 weeks of diabetes was sufficient to 
significantly impair mtBE (black stripe vs solid black), HG did not significantly decrease 
MRC in either the non-diabetic or diabetic neurons. Consistent with the ability of in vivo 
therapy with KU-596 to improve mtBE [298], addition of 1μM KU-596 significantly 
improved OCR, MRC and SRC of non-diabetic and diabetic neurons regardless of the 
glucose concentration. MRC reflects the rate of maximal electron transport and substrate 
oxidation achievable in the absence of limits imposed by the inner mitochondrial 
membrane proton gradient, while SRC indicates the energy reserve available to respond to 
further environmental demands. The decrease in MRC and SRC suggests that electron 
transport in the diabetic mitochondria was impaired, and this deficit was clearly improved 
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Figure 2.3.1.2 KU-596 improves mBE in hyperglycemically stressed WT diabetic 
neurons. 
Adult sensory neurons were isolated from non-diabetic or diabetic WT mice and treated 
+/- 1μM KU-596 overnight in medium containing 6.1 mM basal glucose (BG). 
Hyperglycemia (HG) was then induced in some cultures for 24 hrs by raising the total 
glucose concentration to 26.1 mM.  A) KU-596 improves OCR in WT non-diabetic sensory 
neurons under BG and HG conditions. B) KU-596 improves OCR in WT diabetic sensory 
neurons under BG and HG conditions. C) Quantification of MRC. D) Quantification of 
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SRC.*, p<0.05 vs BG; ^, p<0.05 vs HG; **, p<0.05 vs non-diabetic BG. Results are from 
4-5 wells of neurons per group that were obtained from 8 non-diabetic or diabetic mice. 
 
2.3.1.3 Hsp70 is Necessary for KU-596 to Improve mtBE in Hyperglycemically 
Stressed Sensory Neurons. 
Mechanistically, previous data supported that Hsp70 was necessary for the drug to 
improve DPN when administered in vivo [298]. However, whether Hsp70 may have 
directly or indirectly contributed to improved nerve function was unclear. To determine if 
neuronal Hsp70 was needed to improve mtBE, the above studies were repeated using 
sensory neurons isolated from non-diabetic or diabetic Hsp70 KO mice.  
In contrast to the response in WT mice, diabetes suppressed, but did not sufficiently 
decrease MRC and SRC to a level that was significantly different from the non-diabetic 
Hsp70 KO mice (black stripe vs black bar) (Figs. 2.3.1.3.A, C and D). More unexpected 
was that KU-596 treatment improved MRC and SRC in non-diabetic and diabetic Hsp70 
KO neurons that were incubated in BG. On the other hand, when subjected to HG stress, 
KU-596 treatment could not improve MRC in either non-diabetic or diabetic neurons (Figs. 
2.3.1.3.B, C and D). These data suggest that KU-596 may have some Hsp70-independent 
effects under certain cellular conditions to improve mtBE, but this response is lost in the 
presence of HG stress. Thus, hyperglycemia is shifting efficacy to improve mtBE to 
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Figure 2.3.1.3 KU-596 does not improve mBE in hyperglycemically stressed Hsp70 
KO neurons.  
Adult sensory neurons were isolated from non-diabetic or diabetic Hsp70 KO mice and 
treated +/- 1μM KU-596 overnight in medium containing 6.1 mM basal glucose (BG). 
Hyperglycemia (HG) was then induced in some cultures for 24 hrs by raising the total 
glucose concentration to 26.1 mM.  KU-596 improved OCR in non-diabetic (A) and 
diabetic (B) sensory neurons under BG condition but not after the cells were subjected to 
HG stress. C) Quantification of MRC. D) Quantification of SRC.*, p<0.05 vs BG. Results 





2.3.1.4 KU-596 Improves Glycolytic Capacity in WT Sensory Neurons under Both 
Normal and Hyperglycemic Conditions 
Glycolysis and oxidative phosphorylation are the two-major energy producing 
pathways in the cell. Glycolysis takes place in the cytosol and converts one molecule of 
glucose into two molecules of pyruvate. When oxygen is present, the mitochondria will 
undergo aerobic respiration to reduce pyruvate into acetyl-CoA which enters the citric acid 
cycle (Krebs cycle) inside the mitochondrial matrix. However, if oxygen is not present, 
fermentation of the pyruvate into lactate will occur [344, 345]. Most cells possess the 
ability to shift dynamically between these two processes, adapting to changes in their 
environment. Even in the presence of oxygen, a high rate of glycolysis followed by 
pyruvate and lactate accumulation can supply sufficient energy as compensation. In 
glycolysis, the conversion of glucose to pyruvate and subsequently lactate, results in a 
production and extrusion of protons into the extracellular medium. The Seahorse 
instrument can also measure the acidification rate as Extracellular Acidification Rate 
(ECAR) level along with OCR to indicate the rate of glycolysis. When oxidative 
phosphorylation is disrupted by the ATP synthase inhibitor, Oligomycin shifts the energy 
production to glycolysis to maintain homeostasis, subsequently increasing ECAR. This 
elevated rate of glycolysis is referred to as the Glycolytic Capacity of the cell. 
The trend of ECAR change is similar with OCR level in WT mice. In the WT non-
diabetic mice, KU-596 significantly increased the ECAR regardless of glucose 
concentration (Fig. 2.3.1.4.A). Though diabetes can cause mitochondrial deficiency, 
glycolytic capacity was also decreased. KU-596 again increased the ECAR level under 
normal and hyperglycemia conditions (Fig. 2.3.1.4.B). The ability of ex vivo KU-596 
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treatment to increase glycolytic capacity suggests that modulating molecular chaperones is 
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Figure 2.3.1.4 KU-596 treatment improves glycolysis in WT sensory neurons.  
Sensory neurons were isolated from C57Bl/6 WT non-diabetic and diabetic mice under the 
same condition as on mtBE measurement. We then studied the drug effect on glycolysis 
by injecting ATP synthesis inhibitor, Oligomycin, to shift the energy production to 
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glycolysis. A) KU-596 improved ECAR in WT non-diabetic sensory neurons under both 
normal condition and hyperglycemic condition. B) ECAR level was also increased in WT 
diabetic sensory neurons by KU-596. C) Quantification of Glycolytic Capacity. KU-596 
significantly improved glycolysis in non-diabetic and diabetic sensory neurons under both 
normal and hyperglycemic conditions. *, p<0.05 vs BG; ^, p<0.05 vs HG; **, p<0.05 vs 
non-diabetic BG. Results are from 4-5 wells of neurons per group that were obtained from 
8 non-diabetic or diabetic mice. 
 
2.3.1.5 Hsp70 is Necessary for KU-596 to Improve Glycolysis in Diabetic Sensory 
Neurons under Hyperglycemic Condition. 
        In non-diabetic Hsp70 KO mice, KU-596 treatment improved the glycolytic capacity, 
to an extent that was similar to non-diabetic WT mice (Fig. 2.3.1.5.A). In diabetic Hsp70 
KO sensory neurons, KU-596 also increased the ECAR level under basal glucose condition. 
However, this improvement of ECAR level was completely blocked under hyperglycemic 
stress (Fig. 2.3.1.5.B). This indicates that in diabetic sensory neurons, hyperglycemia 
shifted the improvement in glycolytic capacity by KU-596 to become Hsp70 dependent 
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Figure 2.3.1.5 Hsp70 is necessary for KU-596 to improve glycolysis in diabetic sensory 
neurons under hyperglycemic condition.  
Sensory neurons were isolated from Hsp70 KO mice the same way as described previously. 
We then studied the drug effect on glycolysis. A) KU-596 improved glycolysis in 
Hsp70KO non-diabetic sensory neurons under both normal and hyperglycemic condition. 
B) Though KU-596 has the trend to improve glycolysis in Hsp70 KO diabetic sensory 
neurons under normal condition. However, the drug effect was blocked by 20mm extra 
glucose.  C) Quantification of glycolytic capacity. *, p<0.05 vs BG; ^, p<0.05 vs HG; 
Results are from 3-5 wells of neurons per group that were obtained from 6 non-diabetic or 
diabetic mice. 
 
2.3.2 Decreasing Mitochondrial Oxidative Stress is One Mechanism for KU-596 to 
Improve Mitochondrial Bioenergetics in Diabetic Sensory Neurons 
2.3.2.1 KU-596 Improves mtBE Deficits Caused by Oxidative Damage of H2O2. 
One mechanism for KU-596 to improve cellular bioenergy supply might be through 
decreasing oxidative stress. We first determined if KU-596 can improve a deficiency in 
respiratory capacity that was caused by oxidative stress. We used an immortalized rat 
sensory neuron cell line 50B11 since this cell line has a very low basal level of Hsp70 
77 
 
expression like primary sensory neurons. 50B11 cells were seeded into each well of a 96-
well plate at the density of 4×104 and maintained in DMEM medium with 10% FBS. After 
24h, the medium was changed into DMEM with 1% FBS and the cells were treated with 
100nM, 500nM, 1μM and 10μM KU-596 overnight. On the next day, the cells were 
stressed with 0.5mM H2O2 for 2 hours and transferred to the Seahorse XF96 analyzer to 
measure mtBE. H2O2 largely decreased the OCR elevation in response to FCCP, however, 
KU-596 increased the FCCP response in a dose-dependent manner (Figs. 2.3.2.1.A and B). 
This result shows that modulating chaperones can protect the mtBE deficiency caused by 
oxidative stress. Glycolytic capacity was also measured and though KU-596 trended to 
increase glycolysis, it was not statistically significant (Fig. 2.3.2.1.C).   
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Figure 2.3.2.1 KU-596 improves mtBE deficits cause by H2O2. 
A) Treatment of 0.5mM H2O2 for 2 hours significantly decreased FCCP response in 50B11 
cells. KU-596 improved it in dose-dependent manner. B) Quantification of MRC indicates 
79 
 
that KU-596 improved mtBE significantly, starting from 1μM. C) Quantification of 
Glycolytic Capacity. *, p<0.05 vs normal medium; ^, p<0.05 vs H2O2 treatment; Results 
are from 5 or 6 wells of neurons per group 
 
2.3.2.2 KU-596 Decreases Oxidative Stress in WT Sensory Neurons 
In diabetes, glucose induced superoxide production within mitochondria is a key 
feature of glucotoxicity. To determine the ex vivo effect of KU-596 treatment on 
mitochondrial superoxide levels, the sensory neurons were stained with MitoSOX Red and 
mitoTracker Deep Red (blue signal) to localize the signal to mitochondria. The intensity of 
the superoxide signal was normalized with the signal from mitoTracker Deep Red to rule 
out absorption differences between different cells. As anticipated, the superoxide signal 
intensity in diabetic WT neurons was much higher than in non-diabetic neurons regardless 
of glucose concentration (Figs. 2.3.2.2.A - C). Subjecting both the non-diabetic and 
diabetic neurons to HG stress significantly increased superoxide levels in both groups (Figs. 
2.3.2.2.A - C) and this was normalized by KU-596 treatment. Since superoxide was low in 
non-diabetic neurons that were maintained in BG, KU-596 showed minimal efficacy in 
decreasing these levels. In contrast, KU-596 decreased the significantly higher level of 
superoxide present in diabetic neurons maintained in BG (blue vs black stripe). Together, 
these data support that modulating chaperones with KU-596 can directly improve mtBE 
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Figure 2.3.2.2 KU-596 decreases mitochondrial superoxide levels in hyper-
glycemically stressed WT neurons. 
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Cells were treated as described in Fig. 2.3.1.2 and mitochondrial superoxide assessed by 
confocal microscopy (A and B) after staining the cells with MitoSox red and MitoTracker 
Deep Red. A) Oxidative stress was increased in non-diabetic sensory neurons subjected to 
HG stress and this was decreased by KU-596 treatment. B) Diabetes increased the level of 
superoxide production regardless of glucose concentration and this was significantly 
decreased by KU-596. C) Quantification of MitoSOX staining intensity normalized to 
MitoTracker Deep Red staining intensity. *, p<0.05 vs BG; ^, p<0.05 vs HG; **, p<0.05 
vs non-diabetic BG. Results are from 3 - 4 wells of neurons per group that were obtained 
from 6 non-diabetic or diabetic mice. 
 
2.3.2.3 Hsp70 is Necessary for KU-596 to Decrease Oxidative Stress in Diabetic 
Sensory Neurons. 
To determine if Hsp70 is necessary for the drug to decrease oxidative stress, sensory 
neurons were isolated from non-diabetic and diabetic Hsp70 KO mice and treated as 
described above. When examining superoxide, neither HG stress nor KU-596 caused any 
significant change in superoxide levels in neurons from non-diabetic Hsp70 KO mice (Figs. 
2.3.2.3.A and C). Although neurons from diabetic WT mice maintained in BG showed a 
significant increase in superoxide, this response was not recapitulated in diabetic Hsp70 
KO neurons maintained in BG. Exposing the diabetic Hsp70 KO neurons to HG stress 
significantly increased superoxide levels and KU-596 was unable to decrease this response 
(Fig. 2.3.2.3.C, purple vs red stripes), in contrast to what was observed in similarly treated 
diabetic WT neurons (Fig. 2.3.2.2.C, purple vs red stripes).  The lack of efficacy in 
decreasing superoxide in the diabetic Hsp70 KO neurons supports that neuronal Hsp70 is 
a key component in the mechanism of action of KU-596. 
The results on mtBE and oxidative stress from WT diabetic sensory neurons, suggest 
that decreased mtBE correlated with increased mitochondrial oxidative stress, which could 
both be improved by KU-596 treatment. However, in diabetic sensory neurons under 
hyperglycemic condition, KU-596 can neither improve the MRC nor mitochondrial 
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superoxide levels. These data support that KU-596 can enhance mitochondrial respiration 
and decrease oxidative stress in diabetic sensory neurons in an Hsp70-dependent manner. 
However, what remains unclear is the cause and effect relationship between improved 
respiration and decreased oxidative stress. Thus, this raises the question: Does KU-596 
improve mitochondrial bioenergetics through reducing oxidative stress, or vice versa? 
Since MnSOD is the main mechanism to detoxify mitochondrial superoxide radicals [346, 
347], we sought to knock down MnSOD by shRNA to increase oxidative stress in 
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Figure 2.3.2.3 KU-596 does not decrease mitochondrial superoxide levels in hyper-
glycemically stressed Hsp70 KO neurons.  
Cells were treated as described in Fig. 2.3.1.3 and mitochondrial superoxide was assessed 
by confocal microscopy (A and B) after staining the cells with MitoSox red and 
MitoTracker Deep Red. A) Oxidative stress was not increased in non-diabetic Hsp70 KO 
sensory neurons subjected to HG stress. B) HG stress increased superoxide production id 
diabetic Hsp70 KO neurons and KU-596 treatment was unable to attenuate this response. 
C) Quantification of MitoSOX staining intensity normalized to MitoTracker Deep Red 
staining intensity. *, p<0.05 vs BG. Results are from 3 - 4 wells of neurons per group that 
were obtained from 6 non-diabetic or diabetic mice. 
 
2.3.2.4 KU-596 Decreases Mitochondrial Oxidative Stress with MnSOD knock 
down. 
To determine if KU-596 improved mtBE by reducing superoxide production, WT 
neurons were treated with recombinant adenoviruses expressing shRNA against murine 
MnSOD or a scrambled shRNA. Infection of adult neurons with the MnSOD shRNA 
adenovirus decreased the expression of MnSOD by about 60% (Fig. 2.3.2.4.A). To 
determine the effect of decreasing MnSOD expression on the production of superoxide 
radicals, we employed electron paramagnetic resonance (EPR) spectroscopy using mito-
TEMPO-H, a mitochondria selective spin trap. This approach was necessary since the 
MnSOD shRNA virus co-expressed EGFP for visualizing the efficiency of viral infection. 
When using MitoSox Red to detect superoxide, this resulted in an overlap between the green 
and red fluorescence signals.    
Neurons from non-diabetic and diabetic WT mice were prepared as described above 
and maintained in BG medium for the knockdown experiments. Relative changes in the 
superoxide signal were quantified by integration of the first EPR peak and normalized to 
total protein content. Knockdown of MnSOD increased the mitochondrial superoxide signal 
about two-fold in non-diabetic sensory neurons (Figs. 2.3.2.4.B and D). However, KU-596 
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did not significantly decrease superoxide levels in non-diabetic neurons following 
knockdown of MnSOD. Consistent with the MitoSox data, diabetes increased the 
superoxide signal relative to that present in non-diabetic neurons treated with the scrambled 
shRNA (Figs. 2.3.2.4.C and D). Downregulating MnSOD expression in the diabetic neurons 
further increased the superoxide signal about 2- fold. KU-596 significantly decreased the 
magnitude of the superoxide signal by 60% in diabetic cells infected with the scrambled and 
by 50% in diabetic neurons infected with the MnSOD shRNA. These data suggest that 
MnSOD may not be necessary for the drug to decrease mitochondrial superoxide, though 
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Figure 2.3.2.4 KU-596 decreased superoxide levels in diabetic neurons following 
downregulation of MnSOD.  
A) MnSOD expression in sensory neurons after infection with MnSOD shRNA adenovirus. 
(B & C) EPR assessment of the effect of MnSOD downregulation and KU-596 treatment 
on the superoxide signal in (B) non-diabetic and (C) diabetic neurons from WT mice.  D) 
Quantification of the area under the curve of the first superoxide signal peak, normalized 
to total protein and expressed as the fold of the non-diabetic plus scrambled shRNA control. 
*, p < 0.05 versus non-diabetic plus scrambled shRNA; **, p < 0.05 versus diabetic neurons 
plus scrambled shRNA; ^, p < 0.05, vs diabetic neurons plus MnSOD shRNA. Results are 
from 6 separate experiments in which 3 - 4 wells of neurons per group were obtained from 
6 non-diabetic or diabetic mice. 
 
2.3.2.5 KU-596 Decreases Mitochondrial Oxidative Stress in Hsp70 Dependent 
Manner with MnSOD knock down. 
We also detected superoxide radicals in Hsp70 KO sensory neurons by EPR following 
knock down of MnSOD. In non-diabetic Hsp70 KO sensory neurons, MnSOD down-
regulation increased mitochondrial superoxide radicals. However, after knocking down 
MnSOD, KU-596 did not have much effect on decreasing superoxide levels (Figs. 
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2.3.2.5.A and C). In diabetic sensory neurons treated with scrambled shRNA, superoxide 
radical levels were slightly increased compared to non-diabetic sensory neurons and KU-
596 did not have much effect. Knocking down MnSOD in Hsp70 KO diabetic sensory 
neurons increased superoxide level compared to neurons that received the scrambled 
shRNA, but KU-596 was unable to decrease the superoxide signal (2.3.2.5.B and C). 
Compared to the WT group, the lack of drug efficacy in diabetic sensory neurons from 
Hsp70 KO mice treated with scrambled shRNA means that Hsp70 is necessary for KU-
596 to decrease mitochondrial oxidative stress. Since KU-596 still decreased superoxide 
levels in  diabetic neurons following MnSOD knock down, there may be other mechanisms 
that contribute to this decline, however, this effect is still Hsp70 dependent (compare purple 
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Figure 2.3.2.5 KU-596 decreases mitochondrial oxidative stress in Hsp70 dependent 
manner with MnSOD knock down. 
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Mitochondrial superoxide levels after knocking down MnSOD were also determined by 
EPR. A) KU-596 effect on Hsp70 KO non-diabetic neurons +/- MnSOD shRNA. B) KU-
596 effect on Hsp70 KO diabetic neurons +/- MnSOD shRNA. C) Quantification of 
superoxide radical level. Unlike in WT sensory neurons. KU-596 cannot decrease 
mitochondrial oxidative stressed in Hsp70 KO neurons.  
 
2.3.2.6 KU-596 Improves mtBE through Reducing Mitochondrial Oxidative Stress. 
Next, the effect of MnSOD downregulation and KU-596 on mtBE in neurons from 
non-diabetic and diabetic mice was assessed. In non-diabetic neurons treated with 
scrambled shRNA, KU-596 didn’t improve mitochondrial respiration and downregulating 
MnSOD in the absence or presence of KU-596 had little effect on mtBE (Fig. 2.3.2.6). As 
expected, diabetic sensory neurons treated with scrambled shRNA showed a markedly 
diminished MRC compared to similarly treated non-diabetic neurons, and this deficit was 
significantly improved by KU-596 (Figs. 2.3.2.6 black and orange). However, MRC was 
also significantly increased following MnSOD downregulation in diabetic neurons and 
treating these neurons with KU-596 did not increase MRC any further (Figs. 2.3.2.6 green 
and blue). Since KU-596 significantly decreased the superoxide signal in diabetic neurons 
treated with MnSOD shRNA (Fig. 2.3.2.4.D), these data suggest that the ability of KU-596 
to improve MRC is not necessarily dependent on decreasing mitochondrial superoxide. 
To determine if the increase in MRC following downregulation of MnSOD in 
diabetic neurons was mainly driven by the increase in superoxide, cells were treated with 
mito-TEMPO-H to scavenge superoxide. In non-diabetic neurons, downregulating 
MnSOD did not increase MRC and neither KU-596 nor mito-TEMPO-H significantly 
improved MRC (Figs. 2.3.2.6). In diabetic neurons, knockdown of MnSOD increased 
MRC and this was significantly decreased by mito-TEMPO-H. This data suggests that an 
increase in superoxide levels is associated with the elevation in MRC following 
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knockdown of MnSOD. KU-596 was unable to improve MRC following MnSOD 



























+ + + + + + + +
+ + + +
+ + + +
^
*
+ - - - - - - -
- -
- - -- - -












Figure 2.3.2.6 KU-596 does not improve MRC following downregulation of MnSOD 
in diabetic neurons. 
Quantification of MRC in WT non-diabetic and diabetic neurons in the presence and 
absence of mito-TEMPO-H and KU-596 following MnSOD downregulation. MnSOD 
down-regulation, KU596 and mito TEMPOH didn’t have much effect on mtBE in non-
diabetic sensory neurons. KU-596 improved OCR in WT diabetic sensory neurons with 
scrambled shRNA and this drug effect was blocked with MnSOD down-regulation. With 
mito TEMPOH treatment, the increase of mtBE caused by MnSOD shRNA was decreased 
and KU-596 didn’t have effect on improving mtBE. **, p < 0.05 versus non-diabetic 
neurons treated with scrambled shRNA; *, p < 0.05, versus diabetic neurons treated with 
scrambled shRNA; ^, p < 0.05, versus diabetic neurons treated with MnSOD shRNA. For 
each figure the results are from 4 separate experiments in which 3 - 4 wells of neurons per 





Chapter 3. Conclusion 
Mitochondrial dysfunction is a major pathogenic contributor to DPN since neurons 
highly depend on mitochondria for their energetic supply. Reduced respiratory chain 
activity is observed in sensory neurons and these bioenergetic abnormalities can contribute 
to the degeneration of peripheral axons [348]. Our previous study has shown that sensory 
neuron mitochondrial bioenergetic defects induced by diabetes can be rescued by 
novologue therapy [299]. In addition to aerobic respiration in mitochondria, glycolysis in 
the cytosol is the other mechanism to produce ATP [344, 345]. Most cells possess the 
ability to shift dynamically between glycolysis and oxidative phosphorylation to help adapt 
to changes in their environment. In this work, we identified that KU-596 improved both 
glycolysis and mitochondrial respiration in sensory neurons. SCs are highly glycolytic, 
delivering lactate to axons, but mitochondrial dysfunction can also cause SC degeneration 
and lead to demyelination [87]. Many cells have the ability to shift energy production 
between oxidative phosphorylation and glycolysis, and many factors can regulate the 
respiration process. In the future, we also need to determine if Hsp70 can reprogram SCs 
from glycolytic to oxidative metabolism to promote remyelination and improve nerve 
functions in DPN. 
In vivo, neurons are polarized cells consisting of relatively small cell bodies, dendrites 
with multiple branches and a thin axon that can extend for meters in peripheral nerves [349]. 
It is important to understand the KU-596 effects both on the cell body and axons. Since 
axons are generated from neurons and can extend for meters in peripheral nerve, neurons 
require specialized mechanisms to efficiently distribute mitochondria to far axonal 
branches where energy is in high demand [349, 350]. Axons are important in action 
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potential generation and synaptic transmission while constant ATP supply supports nerve 
functions, thereby maintaining mitochondrial trafficking and distribution is important in 
axonal physiology [351]. Besides identifying KU-596 can improve overall mitochondrial 
energy production in peripheral nerves, it also deserves further effort to understand if KU-
596 can advance the distribution of mitochondria in peripheral nerve to improve nerve 
functions. 
It has been well known that reducing MnSOD can increase mitochondrial superoxide 
and reactive oxygen species (ROS) in both mitochondria and cytoplasm. In our results, 
MnSOD shRNA decreased the protein expression of MnSOD by about 60% and increased 
mitochondrial superoxide levels. Curiously, this was associated with an increase in 
mitochondrial respiration in diabetic sensory neurons. The increase in superoxide levels 
following downregulation of MnSOD seemed responsible for the increased respiration 
since scavenging mitochondrial ROS with mitoTEMPO blocked the increase in cellular 
respiration in diabetic sensory neurons. This phenomenon was also observed in normal 
kidney cells [352]. Though unexpected, excessive superoxide may be activating redox-
sensitive survival and metabolic pathways, including Akt, ERK, PKC, and MAPK [353, 
354]. Exogenous H2O2 can lead to the activation of MAPK pathways [355, 356]. 
Antioxidants can prevent ROS accumulation and MAPK activation [357, 358], indicating 
ROS is involved in activating MAPK pathways. Though the exact mechanism of how ROS 
regulate MAPK pathway is not known, this might be due to oxidative modifications of 




We clearly show that KU-596 decreased mitochondrial superoxide before and after 
knocking down MnSOD using two independent measures. However, after downregulating 
MnSOD, KU-596 didn’t have any further effect on improving MRC. Since KU-596 can 
decrease the superoxide radical levels after MnSOD knocking down, these data suggest 
that the ability of KU-596 to improve MRC is not necessarily dependent on decreasing 
mitochondrial superoxide. There are other mechanisms can be modulated by Hsp70 to 
improve mtBE. 
Increased mitochondrial oxidative stress can also increase the autophagy response, 
which is a lysosome-mediated degradation process for damaged cellular components [360, 
361]. H2O2 and increased O2
− can mediate autophagy. For example in HeLa cells, MnSOD 
overexpression decreased superoxide radical and autophagy. Knocking down MnSOD with 
siRNA increased mitochondrial superoxide levels and autophagy [362]. Autophagy is 
emerging as an important mediator of pathological responses and engaging in cross-talk 
with ROS in both cell signaling and protein damage. Mitochondrial turnover can be 
accelerated by an autophagic process called mitophagy [363]. Mitophagy removes 
mitochondria via a double membrane autophagolysosome to degrade for recycling [364]. 
After knocking down MnSOD, the increased superoxide radical may induce mitophagy to 
increase mtBE. Though KU-596 can still decrease the superoxide levels, the drug may still 
induce mitophagy to compensate for mtBE. After scavenging superoxide with 
mitoTEMPO, KU-596 did not improve mtBE in the absence of superoxide radicals. This 
means superoxide radical might be important to induce mitophagy to protect mtBE. 
However, the crosstalk between mitophagy, redox signaling and mitochondrial dysfunction 
is still not well understood.  
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The selectivity of mitophagy is controlled by a variety of proteins, including PTEN-
induced putative kinase 1 (PINK1) and Parkin. PINK1 is a mitochondria-targeted serine–
threonine kinase that regulates mitochondrial homeostasis. Initially, PINK1 is stabilized by 
mitochondrial depolarization, and direct or indirect PINK1 activation leads to the 
phosphorylation of parkin and its recruitment into mitochondria [365]. The basal parkin 
expression is low in mitochondrial cristae in proliferating cells [366], but parkin can be 
largely transported to mitochondria when their mitochondrial membrane potential is 
disrupted by uncoupling agents or ROS [367, 368]. Parkin then stimulates the perinuclear 
accumulation of mitochondria, via a microtubule dependent mechanism, before the 
recruitment of LC3 and the remaining autophagic machinery to stimulate mitochondrial 
degradation [369-372]. Parkin functions to reduce cytochrome c release from damaged 
mitochondria, thereby preventing subsequent apoptosis [373]. PINK1 and Parkin knockout 
mice have a reduced lifespan, locomotor deficits, mitochondrial defects and increased 
oxidative stress [374, 375]. Mutations in parkin are unable to stimulate the degradation of 
damaged mitochondria [371, 372]. Hsp70 is a substrate of parkin and is necessary to 
transport parkin into mitochondrial matrix to facilitate mitochondrial clearance of damaged 
proteins [376]. In Hsp70 KO mice, parkin was unable to translocate, ubiquitinate and 
mediate mitophagy, leading to abnormal changes in mitochondrial morphology, reduced 
muscle respiratory capacity, lipid accumulation, and muscle insulin resistance [343, 377]. 
Parkin overexpression rescued mitochondrial membrane potential loss, abnormal ROS 
accumulation and mitochondrial DNA synthesis under H2O2-induced stress conditions 
[378]. Since KU-596 improved mtBE via Hsp70 in diabetic sensory neurons, it is important 
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to determine if novologue therapy to ameliorate DPN is through reducing neuronal 
mitophagy in a parkin-dependent manner. 
Besides superoxide, there are other factors that can be modulated by KU-596 to 
decrease oxidative stress. KU-596 can also regulate non-mitochondrial ROS producing 
NADPH oxidases (NOX). In diabetic sensory neurons, KU-596 decreased NOX mRNA 
overexpression in an Hsp70 dependent manner. Thioredoxin reductase inhibitory protein 
(TXNIP) can interfere with the antioxidant activity of thioredoxin (Trx) and drive oxidative 
stress. TXNIP is one of the most inducible genes by high glucose in diabetic sensory 
neurons, retina, pancreatic islets and kidneys [379-381]. In mitochondria, TXNIP inhibits 
Trx2 causing oxidative stress, bioenergetics imbalance, mitophagy, and apoptosis. TXNIP 
mRNA level was increased 2 fold in Type 1 diabetic mice and KU-596 therapy decreased 
it to control levels. Moreover, its expression levels can be affected by Hsp70 [380] since 
KU-596 could not decrease its expression in diabetic Hsp70 KO mice [298, 382]. Though 
our results have identified that Hsp70 can attenuate intracellular oxidative stress induced 
by diabetes, it still remains to be identified whether KU-596 inhibits TXNIP 
overexpression directly or due to the alleviation of hyperglycemic/oxidative stress [382]. 
      As a cellular protective mechanism, oxidative stress can activate several cytoplasmic 
factors, including NFκB, p53, mTOR, ERK and MAPK, which can translocate into the 
nucleus and activate transcription of MnSOD. MnSOD is encoded by a nuclear gene, 
synthesized in the cytosol and imported into the mitochondrial matrix through translocases 
on the outer and the inner membrane. The precursor form can be cleaved into the mature 
form and to detoxify only mitochondrial ROS [383, 384]. Before transporting into 
mitochondria, newly synthesized proteins can interact with chaperones in the cytosol, 
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including Hsp90 and Hsp70 [257, 385, 386]. Both MnSOD and Cu/ZnSOD activities were 
significantly decreased in HSP70.1 KO mice compared to WT mice [387, 388]. 
Intracellular Hsp70 helps to transport MnSOD into mitochondria, while mitochondrial 
Hsp70 facilitates MnSOD import into the mitochondrial matrix [388]. This might account 
for higher basal superoxide levels in non-diabetic Hsp70 KO sensory neurons. 
In non-diabetic and diabetic Hsp70 KO sensory neurons incubated in BG, KU-596 
treatment improved mtBE. When subjected to HG stress, KU-596 treatment could not 
improve MRC in either non-diabetic or diabetic neurons. This suggests KU-596 may have 
some Hsp70-independent effects under certain cellular conditions to improve mtBE. Our 
previous RNA-seq study has suggested KU-596 reversed transcriptomic changes 
associated with the inflammatory pathways in an Hsp70-independent manner [298]. 
Though hyperglycemia is shifting KU-596 efficacy to improve mtBE to become more 
Hsp70-dependent, it is unlikely that Hsp70 works alone to promote efficacy against DPN. 
Overexpression of Hsp27 protected diabetic sensory neuropathy development, and this 
correlated with decreased NFκB activities [389]. Hsp40 interacts with Hsp70 to suppress 
amylin misfolding and aggregation to ameliorate Type 2 diabetes [390].  Over-expression 
of Hsp70 alone in motor neurons of SOD1 mutant mouse model of ALS was not sufficient 
to decrease neuronal cell death, while induction of multiple chaperones in SOD1 mice was 
cytoprotective [391, 392]. Thus, induction of other chaperones may also contribute to KU-
596’s ability to improve mtBE. The drug may promote other chaperones that work in 
conjunction with Hsp70 under hyperglycemic stress. 
In summary, this dissertation provides evidence to show novologue therapy improved 
mtBE and decreased mitochondrial oxidative stress of diabetic sensory neuron in an 
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Hsp70-dependent manner. After knocking down MnSOD, KU-596 can still decrease 
mitochondrial oxidative stress but had no further effect on mtBE. This indicates besides 
decreasing mitochondrial oxidative, there are other mechanisms that can be modulated by 
novologues to improve mtBE. This study elucidates the protective mechanism of 
modulating molecular chaperones in the therapeutic management of DPN in patients with 
type 1 and type 2 diabetes. 
Up to now, the drug development strategies targeting DPN have mainly centered on 
inhibiting specific pathogenic pathways factors linking to hyperglycemia, but with limited 
success. The results of this study advance our knowledge about how chaperones antagonize 
the pathogenesis of DPN and extend our assessment of the translational value of 
modulating molecular chaperones to treat DPN. Our data continue to support that 
novologue therapy may provide an innovative and ground breaking approach to treat DPN. 
Though we are not claiming that modulating chaperones is the only universal mechanism 
to treat DPN, the results of this study extend our understanding about the neuroprotective 
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